

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 August 2001 (23.08.2001)

PCT

(10) International Publication Number
WO 01/60393 A1

(51) International Patent Classification⁷: A61K 38/00, 39/40

(21) International Application Number: PCT/US01/05282

(22) International Filing Date: 15 February 2001 (15.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/182,759 16 February 2000 (16.02.2000) US

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: BECHTEL BWXT IDAHO, LLC [US/US];
P.O. Box 1625, Idaho Falls, ID 83415-3899 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(72) Inventors: KEENER, William, K.; 2840 Vesta Street, Idaho Falls, ID 83402 (US). WARD, Thomas, E.; 2870 Disney Drive, Idaho Falls, ID 83404 (US).

(74) Agent: GOODSON, W., Gary; Bechtel BWXT Idaho LLC, P.O. Box 1625, Idaho Falls, ID 83415-3899 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/60393 A1

(54) Title: SELECTIVE DESTRUCTION OF CELLS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS

(57) Abstract: Compositions and methods for selectively killing a cell containing a viral protease are disclosed. The composition is a variant of a protein synthesis inactivating toxin wherein a viral protease cleavage site is interposed between the A and B chains. The variant of the type II ribosome-inactivating protein is activated by digestion of the viral protease cleavage site by the specific viral protease. The activated ribosome-inactivating protein then kills the cell by inactivating cellular ribosomes. A preferred embodiment of the invention is specific for human immunodeficiency virus (HIV) and uses ricin as the ribosome-inactivating protein. In another preferred embodiment of the invention, the variant of the ribosome-inactivating protein is modified by attachment of one or more hydrophobic agents. The hydrophobic agent facilitates entry of the variant of the ribosome-inactivating protein into cells and can lead to incorporation of the ribosome-inactivating protein into viral particles. Still another preferred embodiment of the invention includes a targeting moiety attached to the variants of the ribosome-inactivating protein to target the agent to HIV infectable cells.

**SELECTIVE DESTRUCTION OF CELLS INFECTED WITH HUMAN
IMMUNODEFICIENCY VIRUS**

CONTRACTUAL ORIGIN OF THE INVENTION

5 This invention was made with United States Government support under Contract No. DE-AC07-94ID13223, now Contract No. DE-AC07-99ID13727 awarded by the United States Department of Energy. The United States Government has certain rights in the invention.

10 **RELATED APPLICATION**

 This application claims priority from United States provisional application S/N 60/182,759 filed February 16, 2000 and is incorporated by reference.

BACKGROUND OF THE INVENTION

15 This invention relates to antiviral agents and methods of use thereof. More particularly, the invention relates to antiviral agents that specifically destroy cells infected by viruses that produce a protease in such infected cells. The antiviral agents are activated by the viral protease, thereby specifically targeting the infected cells for destruction. Toxins that target cell surface receptors or antigens on tumor

20 cells have attracted considerable attention for treatment of cancer. E.g., I. Pastan & D. FitzGerald, Recombinant Toxins for Cancer Treatment, 254 Science 1173-1177 (1991); Anderson et al., U.S. Patent Nos. 5,169,933 and 5,135,736; Thorpe et al., U.S. Patent No. 5,165,923; Jansen et al., U.S. Patent No. 4,906,469; Frankel, U.S. Patent No. 4,962,188; Uhr et al., U.S. Patent No. 4,792,447; Masuho et al., U.S.

25 Patent Nos. 4,450,154 and 4,350,626. These agents include a cell-targeting moiety, such as an antigen-binding protein or a growth factor, linked to a plant or bacterial toxin. They kill cells by mechanisms different from conventional chemotherapy, thus potentially reducing or eliminating cross resistance to conventional chemotherapeutic agents.

Ricin and other similar plant toxins, such as abrin, modeccin and viscumin, comprise two polypeptide chains (known as the A and B chains) linked by a disulfide bridge, one chain (the A chain) being primarily responsible for the cytotoxicity and the other chain (the B chain) having sites that enable the molecule to bind to cell surfaces. Such toxins are known as type II ribosome-inactivating proteins or RIPs. F. Stirpe et al., Ribosome-inactivating Proteins from Plants: Present Status and Future Prospects, ¹10 Biotechnology 405-412 (1992).

Ricin is produced in the plant *Ricinus communis* (commonly known as the castor bean plant) via a precursor protein known as "preproricin." Preproricin comprises a single polypeptide chain that includes a leader sequence, the A chain, a linker peptide, and the B chain. The leader sequence is subsequently removed in the organism to yield proricin, which is then cleaved to eliminate the linker region such that the A and B chains remain connected only by a disulfide bond in the mature protein. The toxicity of ricintype toxins operates in three phases: (1) binding to the cell surface via the B chain; (2) penetration of at least the A chain into the cytosol via intracellular organelles, and (3) inhibition of protein synthesis through the A chain cleaving an essential adenine residue from ribosomal RNA. Thus, outside the cell separated A and B chains are essentially nontoxic, because the inherently toxic A chain lacks the ability to bind to cell surfaces and enter the cells in the absence of the B chain. Moreover, preproricin and proricin are also non-toxic, since the activity of the A chain is inhibited in these precursors. It is also known that in ricintype toxins the B chain binds to cell surfaces by virtue of galactose recognition sites, which react with glycoproteins or glycolipids exposed on the cell surface. It has been suggested that the toxicity of the ricin A chain might be exploited in antitumor therapy by replacing the indiscriminately binding B chain with a different targeting component having the ability to bind only to tumor cells. Thus, various immunotoxins have been prepared consisting of a conjugate of whole ricin or a separated ricin A chain and a tumorspecific monoclonal antibody or other targeting component. While previously described immunotoxins comprising ricin are generally suitable for their

specific purposes, they possess certain inherent limitations that detract from their overall utility in treating viral infections. One problem with the known conjugates arises from a structural feature of the A chain from natural ricin. It is known that the natural ricin A chain becomes Nglycosylated during its synthesis, by enzymes
5 present in *Ricinus* cells, and it is thought that the resulting sugar moieties are capable of nonspecific interactions with cell surfaces. Thus, it appears that the known A chain conjugates are capable of a certain amount of binding with non target cells, even in the absence of the natural B chain, thus increasing the toxicity of such immunotoxins toward non-target cells. To partially mitigate this problem,
10 recombinant A chain that lacks carbohydrate residues has been produced in *E. coli*. S.H. Pincus & V.V. Tolstikov, Anti-Human Immunodeficiency Virus Immunoconjugates, 32 Adv. Pharmacol. 205-247 (1995). Another problem with many ricin immunoconjugates arises from the fact that the B chain seems to have an important secondary function in that it somehow assists in the intoxication process,
15 apart from its primary function in binding the ricin molecule to the cell surfaces. This secondary function is lost if the B chain is replaced by a different targeting component, such as a monoclonal antibody. Some researchers have addressed this problem by covalent attachment of affinity reagents to the B chain such that the galactose binding sites are blocked. J.M. Lambert et al., An Immunotoxin Prepared
20 with Blocked Ricin: a Natural Plant Toxin Adapted for Therapeutic Use, 51 Cancer Res. 6236-6242 (1991).

The aforementioned modifications of ricin seek to enhance binding specificity to the outer cell surface by immunotoxins and similar, targeted therapeutic agents. Since certain types of infected cells do not express infection-related surface
25 antigens, such binding specificity represents an inherent limitation. S.H. Pincus & V.V. Tolstikov, *supra*. A targeting-independent agent with a well-defined toxin activation mechanism involving a viral protease would permit the use of nonspecific "targeting" (i.e., cell-binding) molecules, including sugar moieties and fully active ricin B chain. Therapeutic agents designed in this manner could eliminate a broader

spectrum of infected cells, with potentially fewer undesirable side effects. Anti-HIV immunotoxins have been described that include antibodies linked to various toxic moieties via a peptide linker that includes a sequence cleavable by HIV protease. S.H. Pincus & V.V. Tolstikov, *supra*. In some cases, release of the toxic moiety by this protease may render it active, although the specific activation mechanism was not further defined. In the present invention, antibodies or segments thereof are only one of many potential targeting molecules for the therapeutic agents. Moreover, the activation mechanisms are clearly specified in the present invention. One such mechanism relies on protease-dependent cleavage at or near the natural protease activation site for a given toxin, not merely on release from a bulky "carrier" protein (i.e., antibody). S.H. Pincus & V.V. Tolstikov, *supra*. In the case of ricin, the natural site for cleavage by proteolytic activity in *Ricinus* is in a disulfide-circumscribed loop in which one cysteine resides on the A chain and the other resides on the B chain; cleavage yields A and B chains connected by a disulfide bond. Therefore, most embodiments of the present invention that involve ricin include an HIV-protease cleavage sequence fused in-frame to the C-terminus of A chain such that the natural cleavage site is replaced with the HIV-protease site in the disulfide-circumscribed loop. In these embodiments, at least some minimal N-terminal sequence of B chain required to inhibit A chain activity is retained, such that activation requires proteolytic cleavage and reduction of the disulfide bond. In all remaining embodiments, the mechanism of activation involves cleavage of a peptide linker to A chain, thereby separating adenine-like moieties that are chemically attached to the linker. Separation of the adenine-like residues unblocks the active site of ricin and allows A chain activity. Further, the foregoing text describes preferred embodiments (i.e., full B chain functionality, sugar moieties) that are highly compatible with these activation mechanisms. Indeed, these preferred embodiments are not suggested by others. S.H. Pincus & V.V. Tolstikov, *supra*. Certain embodiments of the present invention comprise attachment of hydrophobic moieties for intracellular targeting to sites of viral protease activity,

which is limited in the cytosol. The aforementioned immunotoxins do not possess this aspect of the invention. While attachment of hydrophobic fatty acids to ricin A chain has been presented in terms of enhancing translocation across cell membranes for hypothetical medical applications, a method for activating ricin was not presented. A.V. Kabanov et al., Fatty Acylation of Proteins for Translocation Across Cell Membrane, 1 Biomed. Sci. 33-36 (1990); V.Y. Alakhov et al., Increasing Cytostatic Effects¹ of Ricin A Chain and *Staphylococcus aureus* Enterotoxin A Through *In Vitro* Hydrophobization with Fatty Acid Residues, 12 Biotechnol. Appl. Biochem. 94-98 (1990). Hydrophobization of ricin is likely to increase toxicity to non-target cells, even if cell-surface targeting moieties are attached. A separate, viral-protease-dependent mechanism for activating ricin (and similar toxins) would prevent nonspecific toxicity. The present invention combines such a mechanism with hydrophobization.

In view of the foregoing, it will be appreciated that providing an antiviral agent that is activated only in cells infected with a selected virus, is non-toxic in uninfected cells, and is targeted independently of infection-related antigens, would be a significant advancement in the art. Furthermore, the prior art teaches away from making the present invention because specific embodiments described herein have previously been described as deleterious (B chain activity). Moreover, the prior art fails to describe or suggest elements of the present invention (e.g., means for fatty acid attachment) in combination with a protease-dependent toxin activation mechanism.

BRIEF SUMMARY OF THE INVENTION

It is an object of the present invention to provide an antiviral agent that is toxic to virus-infected cells, but non-toxic to uninfected cells.

It is also an object of the invention to provide an antiviral agent for treating viral infections wherein the virus encodes a protease that is essential to virus replication.

It is another object of the invention to provide a toxin (e.g., ricin) based antiviral agent that maintains the inhibitory functionality of the lectin B chain, whereby the lectin B chain (or a portion thereof) inhibits the activity of the ricin A chain prior to proteolytic cleavage of a linker sequence and reduction of the disulfide bond. It is another object of the invention to provide a ricin- (or similar toxin) based antiviral agent that maintains the galactose-binding functionality of the ricin B chain, which enhances the binding of the antiviral agent to galactose residues on cell surfaces and the cellular internalization of the antiviral agent.

It is still another object of the invention to provide an antiviral agent for treating retroviral infections, including HIV infections.

It is yet another object of the invention to provide a method for treating retroviral infections wherein the virus encodes a protease that is essential to virus replication.

It is also an object of the invention to provide a method for treating HIV infections.

These and other objects can be addressed by providing a composition comprising a compound represented by the formula $(T_m-AXB)H_n$ or $(A-X-B-T_m)-H_n$, wherein A is a protein synthesis inactivating toxin that is inactive until X is digested; X is a peptide susceptible to digestion by a viral protease; B is a lectin, T is a targeting moiety, H is a hydrophobic agent, m is 0 or an integer of at least 1, and n is 0 or an integer of at least 1. In a preferred embodiment of the invention, A is a ricin A chain and B is a ricin B chain or segment thereof. In another preferred embodiment of the invention, X is susceptible to digestion by a retroviral protease, such as a human immunodeficiency virus protease. In an especially preferred embodiment, X is a member selected from the group consisting of SEQ ID NO:12 and SEQ ID NO: 13. Preferably, the targeting moiety is a member selected from the group consisting of antigen-binding proteins, viral surface components and segments thereof, growth factors, lectins, and carbohydrates. Especially preferred targeting moieties include a member selected from the group consisting of antigen-binding proteins, viral surface

components and segments thereof, proteins that bind viral surface components, growth factors, lectins, and carbohydrates. For example, such targeting moieties can include a member selected from the group consisting of antibodies against HIV glycoprotein gp120, antibodies against gp41, and the CD4 protein or segments thereof. As a further example, the targeting moiety can be an antigen-binding protein that binds the CD4 glycoprotein, such as gp120 or a segment thereof. Still another illustrative targeting moiety is a GAG protein segment.

The hydrophobic agent is preferably a member selected from the group consisting of bile acids, sterols, and saturated and unsaturated fatty acids. Preferred bile acids include cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid, isoursodeoxycholic acid, lagodeoxycholic acid, glycocholic acid, taurocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, dehydrocholic acid, hyocholic acid, hyodeoxycholic acid, and mixtures thereof. Preferred sterols include cholestanol, coprostanol, cholesterol, epicholesterol, ergosterol, ergocalciferol, and mixtures thereof. Preferred saturated or unsaturated fatty acid comprise about 4 to 20 carbon atoms, such as butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, eleostearic acid, and mixtures thereof.

Another preferred embodiment of the invention further comprises a pharmaceutically acceptable carrier admixed with the compound.

Still another preferred embodiment of the invention comprises a composition comprising a compound represented by the formula N-X-A or A-X-N, wherein A is a protein synthesis inactivating toxin that is inactive until digestion of X, X is a peptide susceptible to digestion by a viral protease, and N is an adenine moiety or a functional equivalent thereof. Yet another preferred embodiment of the invention comprises a method for treating a human immunodeficiency virus infection comprising administering an effective amount of a composition comprising:

- (a) a member selected from the group consisting of:

(i) a compound represented by the formula $(T_m-AXB)H_n$ or $(AXBT_m)H_n$, wherein A is a protein synthesis inactivating toxin that is inactive until X is digested; X is a peptide susceptible to digestion by a human immunodeficiency virus protease; B is a lectin, T is a targeting moiety, H is a hydrophobic agent, m is 0 or an integer of at least 1, and n is 0 or an integer of at least 1,

(ii)¹ a compound represented by the formula N-X-A or A-X-N, wherein A is a protein synthesis inactivating toxin that is inactive until digestion of X, X is a peptide susceptible to digestion by a human immunodeficiency virus protease, and N is an adenine moiety or functional equivalent thereof, and

(iii) mixtures of (i) and (ii); and

(b) a pharmaceutically acceptable carrier.

A further preferred embodiment of the invention comprises a nucleic acid encoding a peptide represented by the formula A-X-B wherein A is a protein synthesis inactivating toxin that is inactive until digestion of X; X is a peptide susceptible to digestion by a viral protease; and B is a lectin or other targeting moiety.

20 DETAILED DESCRIPTION OF THE INVENTION

Before the present antiviral agents and methods of use thereof for treating viral infections are disclosed and described, it is to be understood that this invention is not limited to the particular configurations, process steps, and materials disclosed herein as such configurations, process steps, and materials may vary somewhat. It is also to be understood that the terminology employed herein is used for the purpose of describing particular embodiments only and is not intended to be limiting since the scope of the present invention will be limited only by the appended claims and equivalents thereof.

The publications and other reference materials referred to herein to describe the background of the invention and to provide additional detail regarding its practice are hereby incorporated by reference. The references discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing
5 herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention.

It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a composition comprising
10 "a carrier" includes reference to two or more of such carriers, reference to "a fatty acid" includes reference to one or more of such fatty acids, and reference to "a targeting moiety" includes reference to two or more of such targeting moieties.

In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below. As used herein,
15 "comprising," "including," "containing," "characterized by," and grammatical equivalents thereof are inclusive or open-ended terms that do not exclude additional, unrecited elements or method steps. "Comprising" is to be interpreted as including the more restrictive terms "consisting of" and "consisting essentially of."

As used herein, "consisting of" and grammatical equivalents thereof exclude
20 any element, step, or ingredient not specified in the claim.

As used herein, "consisting essentially of" and grammatical equivalents thereof limit the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic or characteristics of the claimed invention.

25 As used herein, "protein synthesis inactivating toxin" includes toxins that are ribonucleases, N-glycosidases, or ADP-ribosyltransferases. N-glycosidases are exemplified by the single polypeptide of the plant type I ribosome inactivating proteins (e.g., gelonin, momordin, and saporin), and the "A" chain of the plant type II ribosome-inactivating proteins (e.g., ricin, abrin, modeccin, and the like) and

similar acting bacterial toxins. "Protein synthesis inactivating toxin" also includes the specific ribonucleases that digest a specific phosphodiester bond in the backbone of ribosomal RNA, thereby inactivating the ribosomes and inhibiting protein synthesis. Ribonucleases are exemplified by the fungal toxins alpha-sarcin, mitogillin, and restrictocin, but also include similar acting bacterial toxins. "Protein synthesis inactivating toxin" also includes the ADP-ribosylating component of the ADP-ribosyltransferases, which are proteolytically activated bacterial toxins that ADP-ribosylate, and thus inactivate, components of the protein synthesis machinery (e.g., diphtheria toxin, *Pseudomonas* exotoxin A). Plant ribosome-inactivating proteins (RIPs) are N-glycosidases that cleave the N-glycosidic bond of adenine in a specific ribosomal RNA sequence. Many RIPs are single-chain proteins (type I RIPs), but some (type II RIPs) possess a galactose-specific lectin domain that binds to cell surfaces. J. M. Ford, M. R. Hartley, L. M. Roberts, Ribosome Inactivating Proteins of Plants, 2 Seminars in Cell Biology 15-22 (1991). The type II RIPs are potent toxins, the best known of which is ricin. As used herein, "type II ribosome-inactivating proteins" or "type II RIPs" means two-chain N-glycosidases that cleave the N-glycosidic bond of adenine in a specific ribosomal RNA sequence, wherein the two chains are an A chain, which possesses the N-glycosidase activity, and a B chain, which comprises a galactose-specific lectin domain that binds to cell surfaces. Ricin is the prototypical type II ribosome-inactivating protein, but other such type II RIPs include abrin (from *Abrus precatorius*), modeccin (from *Adenia digitata*), viscumin (from *Viscum album*), and volkensin (from *Adenia volkensii*). C.H. Hung et al., Cloning and Expression of Three Abrin A-chains and Their Mutants Derived by Site-specific Mutagenesis in *Escherichia coli*, 219 Eur. J. Biochem. 83-87 (1994); K.A. Wood et al., Preproabrin: Genomic Cloning, Characterisation and the Expression of the A-chain in *Escherichia coli*, 198 Eur. J. Biochem. 723-732 (1991); C.-H. Hung et al., Primary Structure of Three Distinct Isoabrinins Determined by cDNA Sequencing: Conservation and Significance, 229 J. Mol. Biol. 263-267 (1993); GenBank accession numbers X76644, X76720, X76721, X76722, X54873,

X54872, X55667, A58957; International Application publication no. WO9701636. As used herein, "ricin A chain" means an N-glycosidase of about 32 kDa that digests and inactivates 26S and 28S ribosomal RNA by cleavage of a specific adenine residue located within a highly conserved region of the 26S and 28S ribosomal RNA, as is well known in the art. As used herein, "ricin B chain" means a galactose/N-acetylgalactosamine-binding lectin of about 34 kDa. SEQ ID NO:1 shows a DNA encoding preproricin and translation product thereof, wherein the signal peptide comprises amino acid residues -24 to -1, the A chain comprises amino acid residues 1 to 267, the linker peptide comprises amino acid residues 268 to 279, and the B chain comprises amino acid residues 280 to 541. This sequence is incomplete at the 5' end (L. M. Roberts, J. W. Tregear, J. M. Lord, Molecular Cloning of Ricin, 7 Targeted Diagn Ther 81-97 (1992)) and the entire sequence is given in SEQ NO. 2 and SEQ NO. 3, which follows. SEQ ID NO:2 and SEQ ID NO:3 show other DNAs encoding preproricin and their translation products thereof wherein the signal peptides comprise amino acid residues 35 to -1, the A chains comprise amino acid residues 1 to 267, the linker peptides comprise amino acid residues 268 to 279, and the B chains comprise amino acid residues 280 to 541. Preferred ricin A chains and ricin B chains include the peptides having the amino acid sequences identified as SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and biologically functional equivalents thereof. These functional equivalents include any two-subunit, proteolytically activatable, N-glycosidase toxins that inactivate ribosomes, i.e., type II ribosome-inactivating proteins. Such functional equivalents of the ricin A chain, for example, retain functionality in digesting ribosomal RNA although they may be truncations, deletion variants, or substitution variants of the ricin A chain portions of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3 or include additional amino acid residues attached thereto. Functional equivalents of the ricin A chain may also be derived from any other type I or type II ribosome inactivating protein. Functional equivalents of the ricin B chain, for example, (a) retain functionality of binding to galactose residues on the surface of cells although they

may be truncations, deletion variants, or substitution variants of the ricin B chain portions of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3 or include additional amino acid residues attached thereto; (b) retain functionality for inhibiting activity of the ricin A chain; (c) or both. Carbohydrate moieties may optionally be attached to the A or B chains.

As mentioned above, changes may be made in the structure of the type II ribosome-inactivating protein A chain or B chain while maintaining the desirable N-glycosidase or galactose-binding characteristics thereof. For example, certain amino acid residues may be substituted for other amino acid residues in a protein structure without appreciable loss of activity. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a peptide's sequence and nevertheless obtain a protein with like properties. It is thus contemplated that various changes may be made in the sequence of a type II ribosome-inactivating protein A chain or B chain without appreciable loss of its biological utility or activity.

It is also well understood by the skilled artisan that inherent in the definition of a biologically functional equivalent protein or peptide is the concept that there is a limit to the number of changes that may be made within a defined portion of the molecule and still result in a molecule with an acceptable level of equivalent biological activity. It is also well understood that where certain residues are shown to be particularly important to the biological or structural properties of a protein or peptide, e.g. residues in active sites, such residues may not generally be exchanged. Amino acid substitutions are generally based on the relative similarity of the amino acid side-chains relative to, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. An analysis of the size, shape, and type of the amino acid side-chains reveals, for example, that arginine, lysine, and histidine are all positively charged residues at neutral pH; that alanine, glycine, and serine are all similar in size; and that phenylalanine, tryptophan, and tyrosine all have a generally similar shape. Therefore, based upon these considerations, the following

conservative substitution groups or biologically functional equivalents have been defined: (a) Cys; (b) Phe, Trp, Tyr; (c) Gln, Glu, Asn, Asp; (d) His, Lys, Arg; (e) Ala, Gly, Pro, Ser, Thr; and (f) Met, Ile, Leu, Val. M. Dayhoff et al., Atlas of Protein Sequence and Structure (Nat'l Biomed. Res. Found., Washington, D.C., 1978).

- 5 Based on similar considerations, another grouping of amino acids is as follows: (a) Pro; (b) Ala, Gly; (c) Ser, Thr; (d) Asn, Gln; (e) Asp, Glu; (f) His; (g) Lys, Arg; (h) Cys; (i) Ile, Leu, Met, Val; and (j) Phe, Trp, Tyr. M. Jimenez-Montano & L. Zamora-Cortina, Evolutionary Model for the Generation of Amino Acid Sequences and its Application to the Study of Mammal Alpha-hemoglobin Chains, Proc. VIIth
10 Int'l Biophysics Congress, Mexico City (1981).

To effect more quantitative changes, the hydropathic index of amino acids may be considered. Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics, which are as follows:

isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine
15 (+2.5); methionine (+1.9); alanine (+1.8); glycine (0.4); threonine (0.7); serine (0.8); tryptophan (0.9); tyrosine (1.3); proline (1.6); histidine (3.2); glutamate (3.5); glutamine (3.5); aspartate (3.5); asparagine (3.5); lysine (3.9); and arginine (4.5). The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art. J. Kyte & R. Doolittle, A
20 Simple Method for Displaying the Hydropathic Character of a Protein, 157 J. Mol. Biol. 105-132 (1982). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based on the hydropathic index, the substitution of amino acids whose hydropathic indices are within ± 2 is preferred,
25 within ± 1 is particularly preferred, and within ± 0.5 is even more particularly preferred.

It is also understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent protein. As detailed in U.S. Patent No. 4,554,101, the following hydrophilicity values have been

assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0);
glutamate (+3.0 \pm 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0);
threonine (0.4); proline (0.5 \pm 1); alanine (0.5); histidine (0.5); cysteine (1.0);
methionine (1.3); valine (1.5); leucine (1.8); isoleucine (1.8); tyrosine (2.3);
5 phenylalanine (2.5); tryptophan (3.4).

In making changes based upon similar hydrophilicity values, the substitution
of amino acids whose hydrophilicity values are within \pm 2 is preferred, within \pm 1 is
particularly preferred, and within \pm 0.5 is even more particularly preferred.

As used herein, "viral protease" and similar terms mean proteases coded for
10 by viral nucleic acids and expressed in virus-infected cells. For example, all known
human retroviruses encode their own proteases. E.g., R.A. Katz & A.M. Skalka, *The
Retroviral Enzymes*, 63 *Annu. Rev. Biochem.* 133-173 (1994); K. Von der Helm,
*Retroviral Proteases: Structure, Function and Inhibition from a Non-anticipated Viral
Enzyme to the Target of a Most Promising HIV Therapy*, 377 *Biol. Chem.* 765-774
15 (1996). Retroviral proteases cleave a polyprotein precursor into a reverse
transcriptase, capsid proteins, and other processed products. A variety of other
viruses also encode their own proteases, including herpesviruses, hepatitis C viruses,
rhinoviruses, and picornaviruses. A.K. Patick & K.E. Potts, *Protease Inhibitors as
Antiviral Agents*, 11 *Clin. Microbiol. Rev.* 614-627 (1998); B.D. Korant, *Viral
20 Proteases: An Emerging Therapeutic Target*, 8 *Crit. Rev. Biotechnol.* 149-157
(1988).

As used herein, "human immunodeficiency virus protease cleavage site" and
similar terms mean peptides that are digested by HIV protease. HIV-1 and HIV-2
proteases, although not identical, both cleave a viral GAG precursor protein of HIV-2
25 at two very different sites to yield the same products. J.C. Wu et al., *Synthetic HIV-
2 Protease Cleaves the GAG Precursor of HIV-1 with the Same Specificity as HIV-1
Protease*, 277 *Arch. Biochem. Biophys.* 306-311 (1990). One such site in the GAG
precursor is Val-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-Asn (type 1 cleavage site wherein
cleavage occurs between the tyrosine and proline residues; SEQ ID NO:4). The

second site is Ser-Ala-Thr-Ile-Met-Met-Gln-Arg-Gly-Asn (type 2 cleavage site wherein cleavage occurs between the two methionine residues, SEQ ID NO:11). There are many different sequences cleaved by HIV-1 protease, which generally fall into one of two types exemplified by these two sites: type 1 having Tyr(Phe)-Pro-
5 and type 2 having hydrophobic residues (excluding proline) at the site of cleavage. J. Tözsér et al., Studies on the Symmetry and Sequence Context Dependence of the HIV-1 Proteinase Specificity, 272 J. Biol. Chem. 16807-16814 (1997). This article by Tözsér et al. goes on to conclude that classification of retroviral cleavage sites into two types is an oversimplification and the strong sequence context dependence
10 also raises difficulties for predicting cleavage sites. While the variability of sequences cleaved by HIV protease makes it difficult to predict cleavage sites, models have been successfully generated for the purpose of predicting these sites. K.C. Chou, A Vectorized Sequence-coupling Model for Predicting HIV Protease Cleavage Sites in Proteins, 268 J. Biol. Chem. 16938-16948 (1993); K.C. Chou,
15 Prediction of Human Immunodeficiency Virus Protease Cleavage Sites in Proteins, 233 Anal. Biochem. 1-14 (1996). Proteases from HIV-1 and HIV-2 recognize and cleave the same two types of sequences, although not necessarily the same sequences with the same cleavage efficiencies. Thus, it is possible to construct a therapeutic agent useful for both forms of the virus. HIV-1 is the form prevalent in the Western
20 world, while HIV-2 is typically found in West African patients with AIDS. However, HIV-1 is likely to cause AIDS in West African patients as well.

As used herein, "peptide" means peptides of any length and includes proteins. The terms "polypeptide" and "oligopeptide" are used herein without any particular intended size limitation, unless a particular size is otherwise stated.

25 As used herein, "carbohydrate" means carbohydrate monomers, oligomers, and polymers. There is no particular intended size limitation with respect to carbohydrate oligomers or polymers unless a particular size is otherwise stated.

As used herein, "lectin" means a class of proteins of nonimmunological origin that binds carbohydrates. The scope of lectins that can be used according to

the present invention is limited only by functionality, i.e., binding to carbohydrates and/or inhibiting activity of a protein synthesis inactivating toxin to which it is fused. Segments or portions of lectins are also to be considered within the scope of the term "lectin" provided that such segments or portions retain the carbohydrate-binding and/or toxin-inhibiting function. Representative lectins that can be used according to the present invention include the following: abrin or jequirity bean (*Abrus precatorius*), asparagus pea or lotus or winged pea (*Tetragonolobus purpureas*), avocado (*Persea americana*), bitter pear melon (*Momordica charantia*), broad bean (*Vicia faba*), camels foot tree (*Bauhinia purpurea*), castor bean (*Ricinus communis*), chick pea (*Cicer arietinum*), Mozambique cobra (*Naja mocambique mocambique*), Thailand cobra (*Naja naja laculbia*), concanavalin A or jack bean (*Canavalia ersiformis*), Israel coral tree (*Erythina oxaliiodendron*), daffodil (*Narcissus pseudonarcissus*), eel (*Anguilla anguilla*), elderberry (*Sambucus nigra*), furze or gorse (*Ulex europaeus*), green marine algae (*Cocleum fragile*), hairy vetch (*Vicia villosa*), horse gram (*Dolichos biflorus*), horseshoe crab or limulin (*Limulus polyphemus*), jacalin (*Artocarpus integrifolia*), Japanese wisteria (*Wisteria floribunda*), jimson weed or thorn apple (*Datura stramonium*), Scotch laburnum (*Laburnum alpinum*), lentil (*Lens culinaris*), lima bean (*Phaseolus limensis*), European mistletoe or viscumin (*Viscum album*), mung bean (*Vigna radiata*), mushroom (*Agaricus bisporus*), Osage orange (*Maclura pomifera*), pagoda tree (*Sophora japonica*), pea (*Pisum sativum*), peanut (*Arachis hypogaea*), pokeweed (*Phytolacca americana*), potato (*Solanum tuberosum*), red kidney bean (*Phaseolus vulgaris*), red marine algae (*Plifola plumosa*), Roman snail (*Helix porrata*), scarlet runner bean (*Phaseolus coccineus*), Scotch broom (*Cytisus scoparius*), Siberian pea tree (*Caragana arborescens*), snail-edible (*Helix pomatia*), snail-garden (*Helix aspersa*), snowdrop (*Galanthus nivalis*), soybean (*Glycine max*), spindle tree (*Euonymus europaeus*), sweet pea (*Lathyrus odoratus*), tomato (*Lycopersicon esculentum*), wheat germ (*Triticum vulgaris*), winged bean (*Psophoramus beligonolobus*). Preferred lectins include the B chains of type II RIPS, such as

ricin, abrin, modeccin, viscumin, and volkensin. Additional preferred lectins include tora-mame lectin (from *Phaeolus vulgaris*), phytohemagglutinin (PHA), wheat germ agglutinin, achatinin H, and *Vicia villosa* lectin. Still additional preferred lectins include lectins that bind to T lymphocytes, including mistletoe lectin, *Phaseolus*
5 *vulgaris* leucoagglutinin, and lectins from *Bandeiraea simplicifolia* BS-I, *Bauhinia purpurea*, *Glycine max*, *Lycopersicon esculentum*, *Triticum vulgaris*, *Canavalia ensiformis*, *Lens culinaris*, *Phaseolus coccineus*, and *Wisteria floribunda*. Further additional preferred lectins include lectins that bind to sulfated carbohydrates, such as L-selectin and human galectin 1. Still further preferred lectins include lectins that
10 bind to HIV gp120, including concanavalin A, wheat germ agglutinin, *Lens culinaris* agglutinin, *Vicia faba* agglutinin, *Pisum sativum* agglutinin, and phytohaemagglutinin. Another group of preferred lectins include the B subunits of Shiga and Shiga-like toxins (SLTs), such as the B chains of Shiga toxin, SLT-I, SLT-II, SLT-IIv, and SLT-2e. Still other preferred lectins include jacalin, mannose
15 binding proteins (e.g., concanavalin A), and maltose binding protein.

As used herein, a "pharmaceutically acceptable" component is one that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio. Such materials are pharmaceutically acceptable in that they are
20 nontoxic, do not interfere with drug delivery, and are not for any other reasons biologically or otherwise undesirable.

As used herein, "effective amount" means an amount of a drug or pharmacologically active agent that is nontoxic but sufficient to provide the desired local or systemic effect and performance at a reasonable benefit/risk ratio attending
25 any medical treatment.

As used herein, "administering" and similar terms mean delivering the composition to the individual being treated such that the composition is capable of being circulated systemically to the parts of the body where the viral protease-sensitive linker can be digested by the viral protease, thus cleaving a peptide bond in

a linker that connects the type II ribosome-inactivating protein A chain and the type II ribosome-inactivating protein B chain. After such digestion, however, the A chain and the B chain will still be coupled to each other by a disulfide bond. Thus, the composition is preferably administered to the individual by systemic administration, typically by subcutaneous, intramuscular, or intravenous administration, or intraperitoneal administration. Injectables for such use can be prepared in conventional forms, either as a liquid solution or suspension or in a solid form suitable for preparation as a solution or suspension in a liquid prior to injection, or as an emulsion. Suitable excipients or carriers include, for example, water, saline, dextrose, glycerol, ethanol, and the like; and if desired, minor amounts of auxiliary substances such as wetting or emulsifying agents, buffers, and the like can be added. Other carriers can be used and are well known in the art.

In its most basic embodiment, the present invention comprises a composition and method of use thereof, wherein the composition comprises a type II ribosome-inactivating protein precursor protein, such as proricin, wherein the natural linker is replaced with a viral-protease-cleavable linker. In an especially preferred embodiment of the invention, the natural linker is replaced with an HIV-protease-cleavable linker. Generally, there are two types of sequences cleaved by HIV proteases, which can be identified with some predictability. In certain embodiments, a major advantage of, for example, a proricin variant over typical immunotoxins is that cells in early stages of infection can be killed, thus preventing HIV replication.

Targeting molecules can be added to various sites on the proricin-based agent in addition to or for replacing the targeting activity of the B chain. Targeting molecules include, but are not limited to, CD4 and derivatives thereof; antibodies such as anti-gp120, anti-gp41, and the like; IL-2 segments; gp120 segments; gag segments; fatty acid or other hydrophobic substituents; and mannose-containing carbohydrate moieties. Especially preferred targeting molecules include gp120 segments and fatty acid or other hydrophobic substituents. Fatty acid groups may permit direct translocation of the agent into cells, rendering the activity of the B

chain unnecessary, even though the presence of the B chain or a segment thereof would remain important so that the A chain would be inactive until proteolytically activated by HIV protease. An alternative mechanism for proteolytic activation involves an adenine or similar group attached to an HIV-protease-cleavable extension linker on the A chain, which will inhibit A chain activity until cleaved by HIV protease.

A major advantage of the present invention is that the antiviral agent is activated in viral particles or early-stage infected cells, killing the cells upon infection and effectively preventing the integration of the viral genome into the host genome and preventing the latency/rebound problem. Another major advantage in certain embodiments is that the present invention should be able to enter all HIV susceptible cells, not just cells known to act as host cells for the virus. Moreover, the agent remains inert in a cell until degraded therein, unless the cell is infected with the virus, wherein the viral protease activates the agent.

Human immunodeficiency virus (HIV) is representative of viruses that encode their own protease enzymes that cleave specific sites on viral proteins during the replication process. J. Gatlin et al., Regulation of Intracellular Human Immunodeficiency Virus Type-1 Protease Activity, 244 Virology 87-96 (1998). Examples of other protease-encoding viruses are yellow fever virus and tick-borne encephalitis virus. T.J. Chambers et al., Evidence that the N-terminal Domain of Nonstructural Protein NS3 from Yellow Fever Virus is a Serine Protease Responsible for Site-specific Cleavages in the Viral Polyprotein, 87 Proc. Nat'l Acad. Sci. USA 8898-8902 (1990); K.V. Pugachev et al., Site-directed Mutagenesis of the Tick-borne Encephalitis Virus NS3 Gene Reveals the Putative Serine Protease Domain of the NS3 Protein, 328 FEBS Lett. 115-118 (1993). Vaccinia virus, which is so closely related to the smallpox virus that it was used as the basis for a vaccine against smallpox, apparently uses a protease specifically located within infected cells, R.M.L. Buller et al., Poxvirus Pathogenesis, 55 Microbiol. Rev. 80-122 (1991). The smallpox virus may use a similar protease.

The therapeutic agent described herein is based on type II ribosome-inactivating proteins, such as the protein toxin, ricin, and is generally applicable to viruses that encode site-specific proteases. From this point in the application, ricin will be used as a preferred example of a type II ribosome-inactivating protein, but it is intended that the scope of the invention include any protein synthesis inactivating toxin, as previously defined. As briefly reviewed above, ricin from castor beans comprises two subunits (A and B) connected by a disulfide bond, with carbohydrate chain(s) attached to each. J.M. Lord et al., Ricin: Structure, Mode of Action, and Some Current Applications, 8 FASEB J. 201-208 (1994); U.S. Patent No. 5,622,838.

5 The A subunit is an enzyme that cleaves a critical adenine residue from ribosomal RNA, thereby inactivating ribosomes. The B subunit is a lectin that binds to cell-surface galactose residues and also contributes to cellular internalization of the A-B toxin.

The rationale for using ricin-based therapeutic agents against HIV has been documented. M.G.C.T. Van Oijen et al., Rationale for Use of Immunotoxins in the Treatment of HIV-infected Humans, 5 J. Drug Target 75-91 (1997). Viruses appropriate the metabolic machinery of infected host cells to replicate themselves. By inactivating the machinery for protein synthesis, i.e., ribosomes, and thereby killing infected cells, selective ricin-based agents can prevent the replication of HIV.

15 This strategy relies on attaching targeting molecules that bind to infected cells. There are two major drawbacks to this approach. First, the viral antigens to which the targeting molecules bind may either be shed from the cell surfaces, J.M. Lord et al., *supra*, or occur on free viral particles, not just cell surfaces. Thus the intended targets (infected cells) are not efficiently destroyed. Second, the ricin-plus-targeting

20 molecule conjugates must be administered in large doses, presumably because they are not ideally suited to the complex internalization pathway whereby ricin enters cells. B.M. Simmons et al., Mannose Receptor-mediated Uptake of Ricin Toxin and Ricin A Chain by Macrophages, 261 J. Biol. Chem. 7912-7920 (1986).

25

The present approach involves a modification of native proricin, which is the precursor of ricin that differs only in that the A and B subunits are connected by a peptide linker to form a continuous proricin peptide. Cleavage of proricin by a protease in castor beans (the source of ricin) yields the mature ricin protein. In the present invention, the naturally occurring peptide linker between the ricin A chain and the ricin B chain is replaced by an HIV-protease-cleavable site. Research results suggest that the A¹ and B subunits are not normally separated until ricin reaches the cytoplasm, wherein the connecting disulfide bond is cleaved, J.P. Frenoy et al., Uptake of Injected ¹²⁵I-ricin by Rat Liver *In Vivo*, 284 Biochem. J. 249-257 (1992); hence, a modified peptide linker connecting the A and B subunits should not interfere with cellular internalization of the protein variant. Indeed, internalization of this variant should be significantly more efficient than for immunotoxins that include targeting molecules.

These data strongly suggest that incorporating an HIV-protease-sensitive linker into proricin will produce an agent that selectively kills HIV-infected cells. Moreover, the proricin variant should work against both forms of the virus, HIV-1 and HIV-2, because it has been shown that HIV-2 protease cleaves the polyprotein precursor of HIV-1 with the same specificity as the HIV-1 protease. J.C. Wu et al., *supra*.

The proricin variant will bind to any cell that displays galactose residues on the cell surface. Another route for cellular uptake involves the mannose-containing carbohydrate chains attached to ricin as it is produced in castor beans and as it should be produced in a yeast cell host. These mannose groups are bound by mannose receptors on cell surfaces. B.M. Simmons et al., *supra*. Additional routes for cellular uptake could be engineered by attaching other sugar-binding lectins to the N-terminus of the ricin A chain or the C-terminus of the B chain. Other proteins have been attached to the N-terminus of the A chain without affecting ricin activity or internalization. B. Beaumelle et al., Ricin A Chain Can Transport Unfolded Dihydrofolate Reductase into the Cytosol, 272 J. Biol. Chem. 22097-22102 (1997).

Together, the many possible proricin variants will be able to enter virtually any cell type, but will be activated within and kill only virus-infected cells. Although the preferred embodiment of the present invention, described above, is designed to be activated in cells infected with HIV, it is also possible that other proteases present in the healthy human body might activate the proricin-based therapeutic agent. Therefore, it would be advantageous to increase the selectivity of the therapeutic agent still further.¹ One solution for increasing selectivity would be to insert a linker containing a type 2 HIV-protease-cleavable site into proricin instead of a type 1 cleavable site. A protease found naturally in the human body may cleave one of the linker types, and activate the therapeutic agent. By changing the linker sequence, selectivity for HIV protease may be increased by avoiding linker cleavage by naturally occurring proteases.

A second solution to avoiding activation by nonspecific proteases is to insert amino acid residues into natural, exposed loops of A chain that are also found in the cleavable linker; such insertions cannot significantly reduce A chain activity. Also, these insertions cannot contain sequences cleavable by the viral protease. Therefore, if a host (i.e., human) protease can cleave the linker at a sequence also found in an A-chain loop insertion, the host protease will inactivate the ricin A chain and prevent destruction of uninfected cells.

Another solution to increasing selectivity is to attach a targeting moiety to the proricin variant. Five categories of targeting molecules are discussed herein: (1) Targeting to the surfaces of infected cells displaying viral proteins as the targets, e.g., gp120. Such targeting molecules would include antibodies, viral proteins or portions thereof, and other proteins that bind to such viral components (e.g., CD4). Typical immunotoxins use this type of targeting molecule. (2) Targeting to infectable or susceptible cells. Molecules used for targeting include proteins that bind to CD4. (3) Targeting to virtually any cell. The ricin B chain binds to any cell displaying galactose residues. Mannose chains on ricin A and B chains could bind to mannose receptors. Fatty acids permit internalization into a variety of cells. Lectins other

than the ricin B chain can also be used. (4) Intracellular targeting to the inner surface of the cell membrane for incorporation into viral particles. Fatty acids and/or segments of the GAG protein attached to the antiviral agent will promote this process. Any protein segment to which fatty acids are attached by enzymes *in vivo* can be fused to the antiviral agent. (5) Targeting with viral vectors, such as an HIV-based vector that would ultimately insert DNA encoding the antiviral agent into susceptible cells. One or more of these five different types of targeting strategies can be used.

A preferred targeting molecule for attachment to the modified proricin of the present invention is a molecule that targets the CD4 glycoprotein on cell surfaces or an antibody against an HIV envelope glycoprotein (S.H. Pincus, Therapeutic Potential of Anti-HIV Immunotoxins, 33 Antiviral Res. 1-9 (1996)). As is well-known in the art, attachment of HIV to cells involves the interaction of the HIV gp120 envelope glycoproteins with specific receptors on cell surfaces—the CD4 glycoprotein and members of the chemokine receptor family. R. Wyatt & J. Sodroski, The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens, 280 Science 1884-1888 (1998). The CD4 glycoprotein is expressed on the surface of T lymphocytes, monocytes, dendritic cells, and brain microglia, the main target cells for primate immunodeficiency viruses *in vivo*. Use of CD4 protein or a derivative thereof as a targeting molecule would cause the present invention to bind surface-exposed gp120 and enter HIV-infected cells and cause inactivation of ribosomes in such cells, thus destroying the ability of the cells to produce new HIV proteins. However, this approach would only target cells in the late stage of infection that are expressing viral proteins on the cell surface. The problem at that point is that the viral genome has already been incorporated into the host cell genome. If viral particles are not being actively produced and their proteins displayed on the cell surface, then the cell will avoid the toxic effects of the CD4-based proricin variant. The virus could rebound at a later date upon cellular activation. G. Mathe, The Kinetics of Cancer Cells and of HIV1: The Problems of

Cell and Virus Rebounds and of Latency, 52 Biomed. Pharmacother. 413-420 (1998).

HIV infections of central nervous system (CNS) cells can involve galactosyl ceramide as a receptor, enabling virus entry by a CD4-independent pathway. S.H. Pincus & V.V. Tolstikov, *supra*. Furthermore, infected CNS cells express little or no viral antigens on their surfaces. While these are not major sites of viral replication, such infected cells¹ may represent a barrier to complete elimination of viral replication. Classical immunotoxins are poor candidates for attacking such cells. In contrast, the present embodiments of the invention involving fully functional B chain could readily bind to galactosyl ceramide, yet remain inactive unless HIV protease is encountered. Further, a compatible embodiment involving fatty acid attachment would facilitate crossing of the blood-brain barrier, which is a major impediment to the efficacy of immunotoxins.

Another targeting molecule would be a portion of interleukin-2 (IL-2) that binds to the high-affinity IL-2 receptors found on a subset of activated T-lymphocytes thought to be the main or sole site of HIV replication. However, it has not been demonstrated that this is the sole site in infected humans. S.H. Pincus, *supra*. Furthermore, the expression of IL-2 receptors on the surface of T cells appears to result from HIV infection or the binding of HIV gp120 to CD4 on the T-cell surface, R.W. Finberg et al., Selective elimination of HIV-1-infected Cells with an Interleukin-2 Receptor-specific Cytotoxin, 252 Science 1703-1705 (1991). Therefore, use of a segment of IL-2 on a classical immunotoxin would target infected cells, although T cells activated by non-HIV stimulants would also be eliminated. S.H. Pincus & V.V. Tolstikov, *supra*. However, infected cells targeted in this manner should be at an earlier stage of infection relative to cells targeted by immunotoxins containing CD4 segments or antibodies against viral proteins. A portion of IL-2 has been fused to diphtheria toxin as an anti-HIV "immunotoxin." R.W. Finberg et al., *supra*.

Since use of IL-2 as a targeting molecule on classical immunotoxins could result in destruction of uninfected cells and deleterious health effects, the protease activation mechanism of the present invention will be important to confer additional selectivity. A strategy for attacking viral latency (stable, dormant provirus integrated
5 into host DNA) is to activate infected T cells to express IL-2 receptors and perhaps viral proteins by exposing patients to exogenous HIV gp120. H. Kornfeld, W. W. Cruikshank, S. W.¹ Pyle, J. S. Berman. D. M. Center, Lymphocyte Activation by HIV-1 Envelope Glycoprotein, 335 Nature 6189 (1988). After several hours, treatment with a protease-activated therapeutic agent containing IL-2 would destroy
10 infected cells. Without activation of the provirus, the therapeutic agent would likely be degraded in the cell before it could be activated. Alternatively, use of the carbohydrate-(galactose-) binding B chain or another lectin separately or as part of the toxin-based therapeutic agent could activate infected T cells. B.A. Sela et al., Lymphocyte Activation by Monovalent Fragments of Antibodies Reactive with Cell
15 Surface Carbohydrates, 143 J. Exp. Med. 665-671 (1976); O. Closs et al., Stimulation of Human Lymphocytes by Galactose-specific *Abrus* and *Ricinus* Lectins, 115 J. Immunol. 1045-1048 (1975).

A better approach would be to kill infected cells at a very early stage of infection, i.e. before the integration of the viral genome. To do this would require a
20 different targeting molecule. One possibility is attaching an octapeptide (or derivative thereof) from the HIV envelope glycoprotein gp120. C.B. Pert et al., Octapeptides Deduced from the Neuropeptide Receptor-like Pattern of Antigen T4 in Brain Potently Inhibit Human Immunodeficiency Virus Receptor Binding and T-cell Infectivity, 83 Proc. Nat'l Acad. Sci. USA 9254-9258 (1986). This short sequence is
25 believed to play an important role in HIV attachment to cells. It could be incorporated into the proricin variant at its N-terminus or at another site in the variant. The receptor for this octapeptide is the T4 or CD4 protein. Entry of primate immunodeficiency viruses into the host cell involves the binding of the gp120 envelope glycoprotein to the CD4 glycoprotein, which serves as the primary

receptor. P.D. Kwong et al., Structure of an HIV gp120 Envelope Glycoprotein in Complex with the CD4 Receptor and a Neutralizing Human Antibody, 393 Nature 648-659 (1998). This receptor is also located on membranes of cells in the human brain. Interestingly, patients with AIDS show neuropsychological deficits. This
5 embodiment of the invention could thus enter any cells that attach to HIV particles, but would be activated only when HIV protease is present.

Other portions of viral proteins could also be fused to the proricin variant. One of these is a largely deglycosylated "gp120 core" consisting of a truncated version of the native gp120 with mutations in some of the loops. P.D. Kwong et al.,
10 *supra*; R. Wyatt et al., The Antigenic Structure of the HIV gp120 Envelope Glycoprotein, 393 Nature 705-711 (1998). Several antigenic residues in gp120 interact with the CD4 protein. R. Wyatt et al., *supra*. Peptides based on these data can be fused to the proricin variant. Also, a short segment of the V3 loop of the gp120 protein can bind to "secondary" cell receptors. J.B. Ghiara et al., Crystal
15 Structure of the Principal Neutralization Site of HIV-1, 264 Science 82-85 (1994). This segment could be flanked by cysteine residues to form a disulfide bond in the genetically engineered variant and thereby stabilize the immunogenic secondary structure of the V3 loop segment. A. Zhang et al., A Disulfide-bound HIV-1 V3 Loop Sequence on the Surface of Human Rhinovirus 14 Induces Neutralizing
20 Responses Against HIV-1, 380 Biol. Chem. 365-374 (1999).

Immunogenic peptides that represent epitopes on the HIV gag protein might also serve as targeting molecules. J.M. Claverie et al., T-immunogenic Peptides Are Constituted of Rare Sequence Patterns. Use in the Identification of T Epitopes in the Human Immunodeficiency Virus Gag Protein, 18 J. Eur. Immunol. 1547-1553
25 (1988). The gag segment will direct an agent that contains it to be incorporated into the virus particle forming at the inner surface of the plasma membrane. C.T. Wang et al., Sequence Requirements for Incorporation of Human Immunodeficiency Virus Gag-²-galactosidase Fusion Proteins into Virus-like Particles, 59 J. Med. Virol. 180-188 (1999); M. Bryant & L. Ratner, Myristoylation-dependent Replication and

Assembly of Human Immunodeficiency Virus 1, 87 Proc. Natl Acad. Sci. USA 523-527 (1990). An appropriate segment may include the N-terminus of the Pr55gag protein, which is attached to myristic acid *in vivo*, thereby causing the myristylated protein to associate with the inner surface of the plasma membrane and the nascent virus particle.

Peptide targeting molecules can be coupled to the proricin variant by expression of a recombinant fusion protein, chemical synthesis and attachment, or any other suitable method known in the art. Such techniques for producing recombinant fusion proteins are well-known in the art, and are described generally in, e.g., J. Sambrook & D. Russell, *Molecular Cloning: A Laboratory Manual* (3d ed., 2001). Reagents useful in applying such techniques, such as restriction endonucleases and the like, are widely known in the art and commercially available from any of several vendors.

The activity of HIV protease is regulated such that it is minimal in the cytoplasm and most active inside the virus particle. J. Gatlin et al., *supra*. The activity in the cytoplasm may be sufficient to activate the proricin variant of this invention. This phenomenon of high activity in the viral particle, however, could be used to advantage to kill the cells upon infection, prior to integration of the viral DNA into the host DNA. By attaching fatty acid residues to the proricin variant, it would bind to the inner surface of the cell membrane and be incorporated into the budding virus particle just as fatty-acid-labeled viral proteins are directed to the membrane. M. Bryant & L. Ratner, *supra*. In this sense, the fatty acid is a targeting molecule. Hydrophobic groups other than fatty acids could provide the same function. Fatty acids could be incorporated by chemical treatment with fatty acyl halides or by coupling fatty acids to the proricin via carbodiimide chemistry. Upon secondary infection, when the virus containing the proricin variant fuses with the membrane of a new cell, it would release the HIV-protease-activated proricin variant into the cytoplasm, where the disulfide bond is reduced and the A chain is released, and thereby kills the cell before integration of the viral genome. It may be necessary

to use an HIV-protease-cleavable linker that is not the optimal sequence for cleavage such that activation of the variant is promoted only within virus particles. A second advantage of using a fatty acylated proricin variant is that the fatty acids could promote cellular internalization of the therapeutic agent, V.Y. Alakhov et al.,

- 5 Increasing Cytostatic Effects of Ricin A Chain and *Staphylococcus aureus* Enterotoxin A through In Vitro Hydrophobization with Fatty Acid Residues, 12 Biotechnol. Appl. Biochem. 94-98 (1990), bypassing the complex internalization route for wild-type ricin involving the endoplasmic reticulum. This has been demonstrated with the ricin A chain. V.Y. Alakhov et al., *supra*.

- 10 Mannose residues on the ricin B chain may be required for the lectin binding activity. M. Westby et al., Preparation and Characterization of Recombinant Proricin Containing an Alternative Protease-sensitive Linker Sequence, 3 Bioconjug. Chem. 375-381 (1992). Therefore, a preferred embodiment of the invention involves making the proricin variant in a eukaryotic host, such as yeast, to provide the
15 necessary glycosylation. The mannose residues are also targeting molecules and can direct native ricin to cells displaying mannose receptors, leading to cell intoxication. D.L. Newton et al., *supra*; B.M. Simmons et al., *supra*.

- If one of the targeting molecules mentioned above is used, it may be possible to eliminate one or more of the galactose binding sites of the ricin B chain by point
20 mutations, D.L. Newton et al., *supra*, or deletions. The mannose residues may also be eliminated by expression of a gene construct in a prokaryotic host or by enzymatic removal. However, at least one of the galactose binding sites appears to be required for effective cellular internalization of native ricin. D.L. Newton et al., *supra*. Leaving the galactose binding sites intact allows the possibility that nonspecific entry
25 into cells would occur despite the incorporation of other targeting molecules. Intoxication, however, would still require that the cells expressed a protease that would cleave the modified proricin-based agent. The advantage of leaving one or both galactose binding sites intact is that the internalization of the agent into cells

would be enhanced. Of course, adding fatty acid residues may allow direct cellular internalization of the agent and avoid the need for galactose binding sites.

Viral vectors could also be used to deliver a gene coding for this antiviral agent to human cells. HIV-based vectors capable of accomplishing this are known in the art. E.g., R. Zufferey et al., Self-inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery, 72 J. Virol. 9873-9880 (1998); H. Miyoshi et al., Development of a Self-inactivating Lentivirus Vector, 72 J. Virol. 8150-8157 (1998). Such an HIV-based vector would have the nucleic acid coding for the antiviral agent of the present invention inserted into it. This vector containing the nucleic acid coding for the antiviral agent would then be administered to patients according to methods known in the art. A percentage of the cells in the body would become transduced with this construct and would thereafter continuously produce the antiviral agent. The antiviral agent would circulate in the blood, creating a condition similar to that created by injection of exogenous antiviral agent into the patient. The circulating antiviral agent could enter any HIV infectable cell, but would be activated and kill the cell only in the presence of HIV protease.

In still another embodiment of the invention, one of the termini of the ricin A chain is extended by means of making a fusion protein, then an adenine or adenine-like group is attached chemically. A cysteine residue may be incorporated into the extension to facilitate chemical attachment of the adenine group. The adenine-like group should not contain adenosine since the adenine moiety is likely to be cleaved from the ribose by the A chain. In this embodiment, the X (protease cleavable) linker is contained within the extension and the B chain is removed. The adenine residue would occupy the active site of the ricin A chain and inhibit activity. The extension linker would contain a cleavage site of an HIV protease. Upon cleavage, the linker/adenine would be separated and inhibition would be relieved, activating the ricin A chain. Adenine and pteric acid, an adenine-like molecule, are known inhibitors of ricin. A. Pallanca et al., Uncompetitive Inhibition by Adenine of the RNA-N-glycosidase Activity of Ribosome-inactivating Proteins, 1384 Biochim.

Biophys. Acta 277-284 (1998); J.D. Robertus et al., Structural Analysis of Ricin and Implications for Inhibitor Design, 34 Toxicon 1325-1334 (1996). It should be noted that there are two cysteine residues in the primary sequence of the ricin A chain that do not participate in a disulfide bond and are apparently not conserved among plant and bacterial ricin-like toxins. Y. Kitaoka, Involvement of the Amino Acids Outside the Active-site Cleft in the Catalysis of Ricin A Chain, 257 Eur. J. Biochem. 255-262 (1998). Thus, these two cysteine residues may not be essential to the activity of the ricin A chain. These cysteine residues could be mutated to other residues, leaving only the cysteine in the extension linker. 8-Adeninethiol could be coupled to this cysteine residue with, for example, a bismaleimide reagent. Pteric acid could be coupled to an amine in the linker by carbodiimide chemistry. Other adenine-like molecules and attachment chemistries are possible and are well known in the art.

The gene for the proricin variant according to the present invention is preferably produced by amplifying the intron-free gene for preproricin in castor beans. The preproricin DNA sequence is known, e.g. F.I. Lamb et al., Nucleotide Sequence of Cloned cDNA Coding for Preproricin, 148 Eur. J. Biochem. 265-270 (1985); J.W. Tregear & L.M. Roberts, The Lectin Gene Family of Ricinus communis: Cloning of a Functional Ricin Gene and Three Lectin Pseudogenes, 18 Plant Mol. Biol. 515-525 (1992); K.C. Halling et al., Genomic Cloning and Characterization of a Ricin Gene from Ricinus communis, 13 Nucleic Acids Res. 8019-8033 (1985); L.M. Roberts et al., Molecular Cloning of Ricin, 7 Targeted Diagn. Ther. 81-97 (1992); JP 1985102188-A; U.S. Patent No. 5,622,838. Methods for amplifying selected DNA segments, U.S. Patent No. 4,683,195; U.S. Patent No. 4,683,202; U.S. Patent No. 4,800,159; U.S. Patent No. 4,965,188; PCR Technology: Principles and Applications for DNA Amplification (H. Erlich ed., Stockton Press, New York, 1989); PCR Protocols: A guide to Methods and Applications (Innis et al. eds, Academic Press, San Diego, Calif., 1990), and synthesizing oligonucleotides, S.A. Narang et al., 68 Meth. Enzymol. 90 (1979) (phosphotriester method); E.L. Brown et al., 68 Meth. Enzymol. 109 (1979) (phosphodiester method); U.S. Patent

No. 4,356,270; U.S. Patent No. 4,458,066; U.S. Patent No. 4,416,988; U.S. Patent No. 4,293,652; N.D. Sinha et al., 24 Tetrahedron Lett. 5843 (1983); N.D. Sinha et al., 12 Nucl. Acids Res. 4539 (1984); N.D. Sinha et al., 15 Nucl. Acids Res. 397 (1987); N.D. Sinha et al., 16 Nucl. Acids Res. 319 (1988), are well known in the art.

5 Methods for joining such amplified DNAs and synthetic DNAs are also well known in the art, e.g. J. Sambrook & D. Russell, Molecular Cloning: A Laboratory Manual (3d ed., 2001); T. Maniatis et al., Molecular Cloning: A Laboratory Manual (1982); F. Ausubel et al., Current Protocols in Molecular Biology (1987).

Next, the DNA encoding the preproricin variant containing the HIV protease

10 site is cloned in an appropriate expression vector for expression in a suitable host cell, as is well known in the art. Methods for cloning in these vectors are well known in the art, e.g., Sambrook, *supra*; Maniatis, *supra*; Ausubel, *supra*. Such suitable host cells are preferably eukaryotic cells, but expression in prokaryotic cells is also intended to be within the scope of the present invention. Expression vectors for

15 expression in eukaryotic cells, e.g., yeast, insect, and mammalian cells, and prokaryotic cells, e.g., bacterial cells, are well known in the art and are commercially available from numerous companies or from depositories such as the American Type Culture Collection. Such expression vectors generally contain the necessary promoters, transcription termination signals, translation initiation and

20 termination signals, and the like for expression of the cloned DNA in the selected host cell. The cloned DNA is then expressed in a selected host transformed with the expression vector containing the variant preproricin DNA. Transformation of bacterial and eukaryotic cells is well known in the art and can be carried out by any appropriate method, such as calcium-dependent methods, heat shock,

25 electroporation, and other effective methods and combinations thereof. The expressed protein is then purified, preferably by affinity of the ricin B chain for galactose-labeled agarose beads if the variant contains functional galactose binding sites of the B chain. Such affinity-based purification methods are also well known in the art.

Next, the purified proricin variant is tested for susceptibility to HIV protease and various other proteases to determine if the proricin variant is indeed selectively activated by HIV protease. As a first matter, the HIV protease should digest the proricin variant peptide, resulting in ricin A and B chains linked by a disulfide bond.

- 5 The resulting ricin is chemically reduced and tested for ricin A chain activity against ribosomes using commercial *in vitro* translation kits.

- The proricin variant containing the HIV protease site can be hydrophobized, as briefly described above. This modification has several advantages, including making it easier for the proricin variant to enter cells *in vivo*. Further, the
- 10 hydrophobic agent coupled to the proricin variant has a tendency to direct the proricin variant to the inner surface of the cell membrane, as described above, where it can be incorporated into HIV particles during budding of the HIV particles through the cell membrane. Preferred hydrophobic agents include bile acids, sterols, and saturated and unsaturated fatty acids. Preferred bile acids include cholic acid,
- 15 deoxycholic acid, chenodeoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid, isoursodeoxycholic acid, lagodeoxycholic acid, glycocholic acid, taurocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, dehydrocholic acid, hyocholic acid, hyodeoxycholic acid, and mixtures thereof. Preferred sterols include cholestanol, coprostanol, cholesterol, epicholesterol,
- 20 ergosterol, ergocalciferol, and mixtures thereof. Preferred saturated and unsaturated fatty acids comprise about 4 to 20 carbon atoms, such as butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, eleostearic acid, and mixtures thereof. The hydrophobic agent can be coupled to the proricin variant by chemical
- 25 conjugation or, in appropriate cases, by using enzymes. For example, an alkanolic acid can be coupled to the proricin variant by forming an amide bond between the carboxylic acid group of the alkanolic acid and an amino group of the proricin variant. The amino group can be the N-terminal amino group of the proricin variant and/or one or more of the μ -amino groups of lysine residues. As is well known in

the art, this reaction could be carried out chemically by activating the alkanolic acid by conversion to an acid chloride, and then reacting the acid chloride with the proricin variant to result in formation of the amide bond.

In still another embodiment of the present invention, a targeting moiety is coupled to the proricin variant. For example, a peptide targeting agent can be coupled to the proricin molecule either chemically or by recombinant DNA methodology. In some embodiments, the compositions are constructed by chemically conjugating the targeting moiety to the proricin variant. "Chemically conjugating" the targeting moiety to the proricin variant, as that term is used herein, means covalently bonding the targeting moiety to the proricin variant either directly or by way of a spacer moiety. Such spacer moieties can include heterobifunctional crosslinkers, such as are well known in the art. Peptide portions of the compositions of the present invention can be produced in a genetically engineered organism, such as *E. coli* or yeast, as a "fusion protein." That is, a hybrid DNA containing a sequence of nucleotides encoding the targeting moiety and the proricin variant can be constructed by recombinant DNA technology. This hybrid DNA can be inserted into an organism such that the "fusion protein" encoded by the hybrid DNA is expressed, as described above. The fusion protein can then be purified by standard methods, including affinity chromatography. If the targeting moiety is a relatively short peptide, such peptide can also be chemically synthesized. Methods for synthesis of peptides are well known in the art. E.g., R.B. Merrifield, Solid Phase Peptide Synthesis, 32 Adv. Enzymol. Relat. Areas Mol. Biol. 221-96 (1969); R.B. Merrifield et al., 21 Biochemistry 5020-31 (1982) (solid phase peptide synthesis); Houghten, 82 Proc. Nat'l Acad. Sci. USA 5131-35 (1985) (solid phase peptide synthesis); Hunkapiller et al., 310 Nature 105-111 (1984).

Example 1

In this example there is described an illustrative method for making a modified proricin according to the present invention. A DNA encoding modified

preproricin is assembled from two DNA fragments amplified by PCR using two sets of primers containing the selected modifications. These primers were designed using the Lasergene program (DNASTAR Inc., Madison, Wisconsin). The template for the PCR reaction is cellular DNA isolated from castor bean; this is possible because the preproricin gene contains no introns. The resulting modified protein replaces the first 10 amino acid residues in the native proricin linker, which contains 12 amino acid residues, with the sequence Val-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-Asn (SEQ ID NO:4). This modified linker peptide (SEQ ID NO:12) is a substrate for the HIV protease, which digests the peptide between the tyrosine and proline residues. The nucleotide sequence coding for the altered amino acid residues (SEQ ID NO:5) was chosen using the codons that are most frequently used in baker's yeast, *Saccharomyces cerevisiae*. This nucleotide sequence contains a restriction endonuclease digestion site in the middle portion of the modified sequence. This site, CAATTG, is recognized by the enzyme MfeI, which has no other sites in the preproricin gene sequence. Thus, the strategy for making the modified preproricin gene is to PCR-amplify the entire modified preproricin gene in two segments that overlap in the region encoding the modified linker. The PCR primers for amplifying these fragments are SEQ ID NO:6 and SEQ ID NO: 7 for amplifying the 5' portion of the preproricin gene and SEQ ID NO: 8 and SEQ ID NO:9 for amplifying the 3' portion of the gene. After amplification, both fragments are digested with MfeI and then ligated together to produce a complete, modified preproricin coding sequence (SEQ ID NO:10).

Since bacteria do not properly glycosylate eukaryotic proteins, and the available evidence suggests that proper processing and glycosylation is required for stability, solubility, and galactose binding activity of the modified preproricin, M. Westby et al., *supra*, the modified preproricin gene is expressed in yeast. Yeast glycosylate and process such a protein provided that it contains a typical eukaryotic leader sequence. P.T. Richardson et al., The Expression of Functional Ricin B-chain

in *Saccharomyces cerevisiae*, 950 Biochim. Biophys. Acta 385-394 (1988). Thus the upstream end of the amplified gene includes the entire coding sequence of preproricin instead of merely the coding sequence of the mature, processed protein (i.e., proricin). Although there are a large number of effective yeast expression

5 vectors available in the art, in this example the modified preproricin gene is inserted in the yeast expression vector, pYES2, available commercially from Invitrogen (Carlsbad, California). This vector contains origins of replication and selectable markers for replication and selection in both yeast and *E. coli*. In addition, this vector contains 10 unique restriction sites in its multiple cloning site, the large

10 majority of which do not occur in the modified preproricin gene sequence. The SacI and XhoI sites were chosen for cloning and expression of the preproricin gene. Thus, a SacI site is engineered into the 5' end of the gene using the primer of SEQ ID NO:6, and an XhoI site is engineered into the 3' end of the gene using the primer of SEQ ID NO:9. Therefore, after PCR amplification, besides being digested with

15 MfeI, each fragment is digested with SacI or XhoI, as appropriate; the pYES2 vector is digested with both SacI and XhoI; and the digested preproricin gene fragments and pYES2 vector are mixed and ligated according to methods well known in the art. The sticky ends direct how the various fragments are joined, and experience shows that the vast majority of recovered circular plasmids have the desired structure.

20 After ligation, the ligation mixture is used to transform competent *E. coli* cells according to methods well known in the art. Transformed cells are selected using the ampicillin marker on the pYES2 vector. Plasmid minipreps are prepared from several randomly selected colonies. Colonies containing the desired plasmid are identified by the size of the plasmid compared to the vector and by the presence

25 of DNA fragments of the correct size following digestion with SacI and MfeI and with MfeI and XhoI. A large preparation of the plasmid containing the correct fragments is then prepared according to methods well known in the art and used to transform an appropriate yeast host strain (e.g., INVSc1, Invitrogen) using the

spheroplast procedure or by making yeast cells competent using proprietary reagents (Invitrogen). Transformed cells are selected using the *ura3* marker on the pYES2 vector, and then selected cells are grown and expression of the modified proricin is induced by addition of galactose to the medium. After further growth for expression, the cells are harvested, washed, lysed by agitation with glass beads or by sonication, and a cell-free extract is prepared. The modified proricin is purified from this extract using its galactose-binding activity by chromatography on an affinity column containing either bound galactose or lactose, similar to the way in which recombinant fusion proteins containing the maltose binding protein are purified. Kellerman & Ferenci, 90 Methods in Enzymology 459-463 (1982). Such columns are available commercially, such as from Sigma Chemical Co. (St. Louis, Missouri). The bound protein is specifically eluted from the column with galactose or a galactose-containing molecule.

Example 2

In this example, the HIV-protease-susceptible linker SEQ ID NO:13 is substituted for SEQ ID NO:12 (see Example 1) using methods well known in the art.

Example 3

In this example, a polynucleotide encoding a fusion peptide, comprising yeast alpha factor leader-ricin A chain-HIV protease cleavable linker-ricin B chain containing a phe to gly mutation at the extreme C-terminus-stop signal, was inserted in the pYES2 yeast expression vector. The alpha factor leader allows secretion and translocation to the endoplasmic reticulum where glycosylation can occur. The phe to gly mutation allows for creation of a unique restriction site and exposes hydrophobic residues on the A chain, according to published crystal structure data. E. Rutenber & J.D. Robertus, Structure of Ricin B-chain at 2.5 A Resolution, 10 Proteins 260-269 (1991).

Example 4

In this example, a polynucleotide encoding a fusion peptide, comprising:
[maltose binding protein-factor Xa site-DP178-ricin A chain-HIV protease
cleavable linker-truncated ricin B chain-repeat of hydrophobic val-ser-ile-leu-ile-
5 pro-ile-ile-ala-leu-met-val (SEQ ID NO:14) (duplicated from the C-terminus of the A
chain)-stop signal], was inserted in the pMALp2X *E. coli* expression vector. DP178
is a section of the gp41 ectodomain involved in viral fusion to host cells. It is about
40 amino acid residues in length and has been shown to inhibit infectivity. The
truncated B chain includes the first cys residue and about an additional 7-8 residues.
10 The hydrophobic repeat is intended to facilitate translocation across membranes,
such as the lumen of the endoplasmic reticulum to the cytosol.

Example 5

In this example, a gly-ala-arg-ala-ser (SEQ ID NO:17) myristylation signal
15 sequence (from HIV gag protein) was inserted between the factor Xa cleavage site
and DP178 of the construct of Example 4. The myristylation sequence should
promote attachment of fatty acids *in vivo*, and should direct the therapeutic agent to
an intracellular site of nascent virus particles and HIV protease activity.

Example 6

20 In this example, an "L domain" (pro-pro-pro-pro-tyr, SEQ ID NO:15) and an
ER lumen retention signal (lys-asg-glu-leu, SEQ ID NO:16) are inserted after the
repeat of the hydrophobic sequence from the C-terminus of the A chain of the
construct of Example 5. The short L domain sequence has been fused to proteins
25 other than the viral proteins in which it naturally occurs. It promotes the release of
viral proteins from membranes by an unknown mechanism. The ER lumen retention
signal has been shown to enhance toxicity of the ricin A chain when fused to the C-
terminus thereof.

Example 7

In this example, the procedure of Example 3 was carried out except that a single domain ricin B chain was substituted for the ricin B chain. The single domain ricin B chain contains no glycosylation sites, but has both galactose binding sites.

5

Example 8

Three constructs were prepared for evaluating the concept that highly truncated ricin B chain can inhibit ricin A chain activity and thus permit an HIV-protease-dependent activation mechanism. These constructs were designed for cytosolic expression in yeast, and were expected to kill the cells if the A chain was in active form. Construct A comprises a fusion of ricin A chain-HIV protease cleavable linker-full ricin B chain, in pYES2. Construct B comprises a fusion of ricin A chain-HIV protease cleavable linker truncated at the expected cleavage site, in pYES2. Construct C comprises a fusion of ricin A chain-HIV protease cleavable linker-highly truncated B chain-repeat of hydrophobic sequence (SEQ ID NO:14) duplicated from C-terminus of A chain, in pYES2.

10
15

Yeast containing plasmids A, B, or C were streaked onto semi-solid media lacking uracil and containing glucose, raffinose, or raffinose + galactose. The pYES2-based plasmids were maintained in the cells because they confer the ability to grow in the absence of uracil. After incubation for 5 days at 30°C, the amount of growth was noted. Glucose permits growth but represses synthesis of the encoded agent. Raffinose permits growth but neither represses nor induces synthesis. Galactose alone does not permit growth, but induces synthesis of the encoded agent. Growth was obtained in all cases except for cell containing plasmid B on raffinose + galactose, wherein there was no growth. These results suggest that cleavage at the expected site by HIV protease results in activation of the ricin A chain and cell death. Further, the B chain may be highly truncated, albeit with a hydrophobic extension, and still inhibit A chain activity.

20
25

WE CLAIM:

1. A composition comprising a compound represented by the formula $(T_m-A-X-B)-H_n$ or $(A-X-B-T_m)-H_n$, wherein A is a protein synthesis inactivating toxin that is inactive until X is digested; X is a peptide susceptible to digestion by a viral protease; B is a lectin or a segment thereof, T is a targeting moiety, H is a hydrophobic agent, m is 0 or an integer of at least 1, and n is 0 or an integer of at least 1.
2. The composition of claim 1 wherein said viral protease is from a retrovirus, picornavirus, rhinovirus, hepatitis C virus, or herpesvirus.
3. The composition of claim 1 wherein A is a ricin A chain and B is a ricin B chain.
4. The composition of claim 1 wherein X is a member selected from the group consisting of SEQ ID NO:12 and SEQ ID NO: 13.
5. The composition of claim 1 wherein said targeting moiety is a member selected from the group consisting of antigen-binding proteins, viral surface components and segments thereof, proteins that bind viral surface components, growth factors, lectins, and carbohydrates.
6. The composition of claim 5 wherein said targeting moiety is a member selected from the group consisting of antibodies against gp120, antibodies against gp41, and the CD4 protein or segments thereof.
7. The composition of claim 5 wherein said targeting moiety is an antigen-binding protein that binds the CD4 glycoprotein.

8. The composition of claim 7 wherein the protein that binds the CD4 glycoprotein is gp120 or a segment thereof.

9. The composition of claim 1 wherein said targeting moiety is a GAG protein segment.

10. The composition of claim 1 wherein said hydrophobic agent is a member selected from the group consisting of bile acids, sterols, and saturated and unsaturated fatty acids.

11. The composition of claim 10 wherein said hydrophobic agent is a bile acid selected from the group consisting of cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid, isoursodeoxycholic acid, lagodeoxycholic acid, glycocholic acid, taurocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, dehydrocholic acid, hyocholic acid, hyodeoxycholic acid, and mixtures thereof.

12. The composition of claim 10 wherein said hydrophobic agent is a sterol selected from the group consisting of cholestanol, coprostanol, cholesterol, epicholesterol, ergosterol, ergocalciferol, and mixtures thereof.

13. The composition of claim 10 wherein said hydrophobic agent is a saturated or unsaturated fatty acid comprising about 4 to 20 carbon atoms.

14. The composition of claim 13 wherein said saturated or unsaturated fatty acid is a member selected from the group consisting of butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, eleostearic acid, and mixtures thereof.

15. The composition of claim 1 further comprising a pharmaceutically acceptable carrier admixed with the compound.

5 16. The composition of claim 1 wherein A, B, or both are from ADP-ribosyltransferases.

17. The composition of claim 1 wherein T comprises a myristylation signal sequence.

10

18. A composition comprising a compound represented by the formula N-X-A or A-X-N, wherein A is a protein synthesis inactivating toxin that is inactive until X is digested, X is a peptide susceptible to digestion by a viral protease, and N is an adenine moiety or functional equivalent thereof.

15

19. The composition of claim 18 wherein A is a ricin A chain.

20. The composition of claim 18 wherein X is a member selected from the group consisting of SEQ ID NO:12 and SEQ ID NO:13.

20

21. The composition of claim 18 wherein N is adenine.

22. The composition of claim 18 wherein N is a member selected from the group consisting of pterioic acid and 8-adeninethiol.

25

23. A method for treating a human immunodeficiency virus infection comprising administering an effective amount of a composition comprising:

(a) a member selected from the group consisting of:

(i) a compound represented by the formula $(T_m-A-X-B)-H_n$ or $(A-X-B-T_m)-H_n$, wherein A is a protein synthesis inactivating toxin that is inactive until X is digested; X is a peptide susceptible to digestion by a human immunodeficiency virus protease; B is a lectin or a segment thereof, T is a targeting moiety, H is a hydrophobic agent, m is 0 or an integer of at least 1, and n is 0 or an integer of at least 1,

(ii)¹ a compound represented by the formula $N-X-A$ or $A-X-N$, wherein A is a protein synthesis inactivating protein that is inactive until X is digested, X is a peptide susceptible to digestion by a human immunodeficiency virus protease, and N is an adenine moiety or functional equivalent thereof, and

(iii) mixtures of (i) and (ii); and

(b) a pharmaceutically acceptable carrier.

24. The method of claim 23 wherein A is a ricin A chain and B is a ricin B chain.

25. The method of claim 23 wherein X is a member selected from the group consisting of SEQ ID NO:12 and SEQ ID NO: 13.

26. The method of claim 23 wherein said targeting moiety is a member selected from the group consisting of antigen-binding proteins, viral surface components and segments thereof, proteins that bind viral surface components, growth factors, lectins, and carbohydrates.

27. The method of claim 26 wherein said targeting moiety is an antigen-binding protein that binds the CD4 glycoprotein.

28. The method of claim 27 wherein the protein that binds the CD4 glycoprotein is gp120 or a segment thereof.

29. The method of claim 23 wherein said targeting moiety is a GAG protein segment.

30. The method of claim 23 wherein said hydrophobic agent is a member selected from the group consisting of bile acids, sterols, and saturated and unsaturated fatty acids.

10

31. The method of claim 30 wherein said hydrophobic agent is a bile acid selected from the group consisting of cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, ursocholic acid, ursodeoxycholic acid, isoursodeoxycholic acid, lagodeoxycholic acid, glycocholic acid, taurocholic acid, glycodeoxycholic acid, glycochenodeoxycholic acid, dehydrocholic acid, hyocholic acid, hyodeoxycholic acid, and mixtures thereof.

15

32. The method of claim 30 wherein said hydrophobic agent is a sterol selected from the group consisting of cholestanol, coprostanol, cholesterol, epicholesterol, ergosterol, ergocalciferol, and mixtures thereof.

20

33. The method of claim 30 wherein said hydrophobic agent is a saturated or unsaturated fatty acid comprising about 4 to 20 carbon atoms.

25

34. The method of claim 33 wherein said saturated or unsaturated fatty acid is a member selected from the group consisting of butyric acid, valeric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, eleostearic acid, and mixtures thereof.

35. A nucleic acid encoding a peptide represented by the formula A-X-B wherein A is a protein synthesis inactivating toxin that is inactive until X is digested; X is a peptide susceptible to digestion by a human immunodeficiency virus protease; and B is a lectin or a segment thereof or other peptide targeting moiety.

5

36. The nucleic acid of claim 35 wherein A is a ricin A chain and B is a ricin B chain.

37. The nucleic acid of claim 35 wherein X is a member selected from the group consisting of SEQ ID NO:12 and SEQ ID NO:13.

10

38. A composition comprising a compound represented by the formula A-X-B, wherein A is a protein synthesis inactivating toxin that is inactive until X is digested; X is a peptide susceptible to digestion by a viral protease; and B is a lectin or a segment thereof.

15

39. The composition of claim 38 wherein said viral protease is from a retrovirus, picornavirus, rhinovirus, hepatitis C virus, or herpesvirus.

40. The composition of claim 38 wherein X is a member selected from the group consisting of SEQ ID NO:12 and SEQ ID NO: 13.

20

41. The composition of claim 38 wherein A is a ricin A chain and B is a ricin B chain.

42. The composition of claim 38 wherein A is a ricin A chain and B is a fragment of a ricin B chain.

25

43. The composition of claim 38 further comprising a pharmaceutically acceptable carrier admixed with the compound.

44. A composition comprising a compound represented by the formula A-X-B, wherein A is a ricin A chain that is inactive until X is digested; X is a peptide susceptible to digestion by a viral protease and is a member selected from the group
5 consisting of SEQ ID NO:12 and SEQ ID NO:13; and B is a ricin B chain or a segment thereof.

45. The composition of claim 44 further comprising a pharmaceutically acceptable carrier admixed with the compound.

SEQUENCE LISTING

<110> Keener, William K.
Ward, Thomas E.

5 <120> SELECTIVE DESTRUCTION OF CELLS INFECTED WITH HUMAN
IMMUNODEFICIENCY VIRUS

<130> LIT-PI-529

<160> 17

<210> 1

<211> 1698

10 <212> DNA

<213> Ricinus communis

<308> Genbank E00351

<400> 1

15 atg tat gca gtg gca aca tgg ctt tgt ttc gga tcc acc tca ggg 45
Met Tyr Ala Val Ala Thr Trp Leu Cys Phe Gly Ser Thr Ser Gly
-20 -15 -10

tgg tct ttc aca tta gag gat aac aac ata ttc ccc aaa caa tac 90
Trp Ser Phe Thr Leu Glu Asp Asn Asn Ile Phe Pro Lys Gln Tyr
-5 1 5

20 cca att ata aac ttt acc aca gcg ggt gcc act gtg caa agc tac 135
Pro Ile Ile Asn Phe Thr Thr Ala Gly Ala Thr Val Gln Ser Tyr
10 15 20

25 aca aac ttt atc aga gct gtt cgc ggt cgt tta aca act gga gct 180
Thr Asn Phe Ile Arg Ala Val Arg Gly Arg Leu Thr Thr Gly Ala
25 30 35

gat gtg aga cat gat ata cca gtg ttg cca aac aga gtt ggt ttg 225
Asp Val Arg His Asp Ile Pro Val Leu Pro Asn Arg Val Gly Leu
40 45 50

30 cct ata aac caa cgg ttt att tta gtt gaa ctc tca aat cat gca 270
Pro Ile Asn Gln Arg Phe Ile Leu Val Glu Leu Ser Asn His Ala
55 60 65

	gag ctt tct gtt aca tta gcc ctg gat gtc acc aat gca tat gtg	315
	Glu Leu Ser Val Thr Leu Ala Leu Asp Val Thr Asn Ala Tyr Val	
		70 75 80
5	gtc ggc tac cgt gct gga aat agc gca tat ttc ttt cat cct gac	360
	Val Gly Tyr Arg Ala Gly Asn Ser Ala Tyr Phe Phe His Pro Asp	
		85 90 95
	aat cag gaa gat gca gaa gca atc act cat ctt ttc act gat gtt	405
	Asn Gln Glu Asp Ala Glu Ala Ile Thr His Leu Phe Thr Asp Val	
		100 105 110
10	caa aat cga tat aca ttc gcc ttt ggt ggt aat tat gat aga ctt	450
	Gln Asn Arg Tyr Thr Phe Ala Phe Gly Gly Asn Tyr Asp Arg Leu	
		115 120 125
	gaa caa ctt gct ggt aat ctg aga gaa aat atc gag ttg gga aat	495
	Glu Gln Leu Ala Gly Asn Leu Arg Glu Asn Ile Glu Leu Gly Asn	
15		130 135 140
	ggt cca cta gag gag gct atc tca gcg ctt tat tat tac agt act	540
	Gly Pro Leu Glu Glu Ala Ile Ser Ala Leu Tyr Tyr Tyr Ser Thr	
		145 150 155
	ggt ggc act cag ctt cca act ctg gct cgt tcc ttt ata att tgc	585
20	Gly Gly Thr Gln Leu Pro Thr Leu Ala Arg Ser Phe Ile Ile Cys	
		160 165 170
	atc caa atg att tca gaa gca gca aga ttc caa tat att gag gga	630
	Ile Gln Met Ile Ser Glu Ala Ala Arg Phe Gln Tyr Ile Glu Gly	
		175 180 185
25	gaa atg cgc acg aga att agg tac aac cgg aga tct gca cca gat	675
	Glu Met Arg Thr Arg Ile Arg Tyr Asn Arg Arg Ser Ala Pro Asp	
		190 195 200
	cct agc gta att aca ctt gag aat agt tgg ggg aga ctt tcc act	720
	Pro Ser Val Ile Thr Leu Glu Asn Ser Trp Gly Arg Leu Ser Thr	
30		205 210 215
	gca att caa gag tct aac caa gga gcc ttt gct agt cca att caa	765
	Ala Ile Gln Glu Ser Asn Gln Gly Ala Phe Ala Ser Pro Ile Gln	
		220 225 230
	ctg caa aga cgt aat ggt tcc aaa ttc agt gtg tac gat gtg agt	810
35	Leu Gln Arg Arg Asn Gly Ser Lys Phe Ser Val Tyr Asp Val Ser	
		235 240 245

	ata tta atc cct atc ata gct ctc atg gtg tat aga tgc gca cct	855
	Ile Leu Ile Pro Ile Ile Ala Leu Met Val Tyr Arg Cys Ala Pro	
	250 255 260	
5	cca cca tcg tca cag ttt tct ttg ctt ata agg cca gtg gta cca	900
	Pro Pro Ser Ser Gln Phe Ser Leu Leu Ile Arg Pro Val Val Pro	
	265 270 275	
	aat ttt aat gct gat gtt tgt atg gat cct gag ccc ata gtg cgt	945
	Asn Phe Asn Ala Asp Val Cys Met Asp Pro Glu Pro Ile Val Arg	
	280 285 290	
10	atc gta ggt cga aat ggt cta tgt gtt gat gtt agg gat gga aga	990
	Ile Val Gly Arg Asn Gly Leu Cys Val Asp Val Arg Asp Gly Arg	
	295 300 305	
	ttc cac aac gga aac gca ata cag ttg tgg cca tgc aag tct aat	1035
	Phe His Asn Gly Asn Ala Ile Gln Leu Trp Pro Cys Lys Ser Asn	
15	310 315 320	
	aca gat gca aat cag ctc tgg act ttg aaa aga gac aat act att	1080
	Thr Asp Ala Asn Gln Leu Trp Thr Leu Lys Arg Asp Asn Thr Ile	
	325 330 335	
20	cga tct aat gga aag tgt tta act act tac ggg tac agt ccg gga	1125
	Arg Ser Asn Gly Lys Cys Leu Thr Thr Tyr Gly Tyr Ser Pro Gly	
	340 345 350	
	gtc tat gtg atg atc tat gat tgc aat act gct gca act gat gcc	1170
	Val Tyr Val Met Ile Tyr Asp Cys Asn Thr Ala Ala Thr Asp Ala	
	355 360 365	
25	acc cgc tgg caa ata tgg gat aat gga acc atc ata aat ccc aga	1215
	Thr Arg Trp Gln Ile Trp Asp Asn Gly Thr Ile Ile Asn Pro Arg	
	370 375 380	
30	tct agt cta gtt tta gca gcg aca tca ggg aac agt ggt acc aca	1260
	Ser Ser Leu Val Leu Ala Ala Thr Ser Gly Asn Ser Gly Thr Thr	
	385 390 395	
	ctt acg gtg caa acc aac att tat gcc gtt agt caa ggt tgg ctt	1305
	Leu Thr Val Gln Thr Asn Ile Tyr Ala Val Ser Gln Gly Trp Leu	
	400 405 410	
35	cct act aat aat aca caa cct ttt gtt aca acc att gtt ggg cta	1350
	Pro Thr Asn Asn Thr Gln Pro Phe Val Thr Thr Ile Val Gly Leu	
	415 420 425	

	tat ggt ctg tgc ttg caa gca aat agt gga caa gta tgg ata gag 1395	
	Tyr Gly Leu Cys Leu Gln Ala Asn Ser Gly Gln Val Trp Ile Glu	
	430 435 440	
5	gac tgt agc agt gaa aag gct gaa caa cag tgg gct ctt tat gca 1440	
	Asp Cys Ser Ser Glu Lys Ala Glu Gln Gln Trp Ala Leu Tyr Ala	
	445 450 455	
	gat ggt tca ata cgt cct cag caa aac cga gat aat tgc ctt aca 1485	
	Asp Gly Ser Ile Arg Pro Gln Gln Asn Arg Asp Asn Cys Leu Thr	
	460 465 470	
10	agt gat tct aat ata cgg gaa aca gtt gtt aag atc ctc tct tgt 1530	
	Ser Asp Ser Asn Ile Arg Glu Thr Val Val Lys Ile Leu Ser Cys	
	475 480 485	
	ggc cct gca tcc tct ggc caa cga tgg atg ttc aag aat gat gga 1575	
	Gly Pro Ala Ser Ser Gly Gln Arg Trp Met Phe Lys Asn Asp Gly	
15	490 495 500	
	acc att tta aat ttg tat agt gga ttg gtg tta gat gtg agg cga 1620	
	Thr Ile Leu Asn Leu Tyr Ser Gly Leu Val Leu Asp Val Arg Arg	
	505 510 515	
	tcg gat ccg agc ctt aaa caa atc att ctt tac cct ctc cat ggt 1665	
20	Ser Asp Pro Ser Leu Lys Gln Ile Ile Leu Tyr Pro Leu His Gly	
	520 525 530	
	gac cca aac caa ata tgg tta cca tta ttt tga 1698	
	Asp Pro Asn Gln Ile Trp Leu Pro Leu Phe	
	535 540	
25	<210> 2	
	<211> 1731	
	<212> DNA	
	<213> Ricinus communis	
	<308> Genbank X52908	
30	<400> 2	
	atg aaa ccg gga gga aat act att gta ata tgg atg tat gca gtg 45	
	Met Lys Pro Gly Gly Asn Thr Ile Val Ile Trp Met Tyr Ala Val	
	-35 -30 -25	

	gca	aca	tgg	ctt	tgt	ttt	gga	tcc	acc	tca	ggg	tgg	tct	ttc	aca	90
	Ala	Thr	Trp	Leu	Cys	Phe	Gly	Ser	Thr	Ser	Gly	Trp	Ser	Phe	Thr	
	-20					-15					-10					
5	tta	gag	gat	aac	aac	ata	ttc	ccc	aaa	caa	tac	cca	att	ata	aac	135
	Leu	Glu	Asp	Asn	Asn	Ile	Phe	Pro	Lys	Gln	Tyr	Pro	Ile	Ile	Asn	
	-5				-1	1				5					10	
	ttt	acc	aca	gcg	ggt	gcc	act	gtg	caa	agc	tac	aca	aac	ttt	atc	180
	Phe	Thr	Thr	Ala	Gly	Ala	Thr	Val	Gln	Ser	Tyr	Thr	Asn	Phe	Ile	
					15					20					25	
10	aga	gct	ggt	cgc	ggt	cgt	tta	aca	act	gga	gct	gat	gtg	aga	cat	225
	Arg	Ala	Val	Arg	Gly	Arg	Leu	Thr	Thr	Gly	Ala	Asp	Val	Arg	His	
					30					35					40	
	gaa	ata	cca	gtg	ttg	cca	aac	aga	gtt	ggt	ttg	cct	ata	aac	caa	270
	Glu	Ile	Pro	Val	Leu	Pro	Asn	Arg	Val	Gly	Leu	Pro	Ile	Asn	Gln	
15					45					50					55	
	cgg	ttt	att	tta	gtt	gaa	ctc	tca	aat	cat	gca	gag	ctt	tct	gtt	315
	Arg	Phe	Ile	Leu	Val	Glu	Leu	Ser	Asn	His	Ala	Glu	Leu	Ser	Val	
					60					65					70	
20	aca	tta	gcg	ctg	gat	gtc	acc	aat	gca	tat	gtg	gtc	ggc	tac	cgt	360
	Thr	Leu	Ala	Leu	Asp	Val	Thr	Asn	Ala	Tyr	Val	Val	Gly	Tyr	Arg	
					75					80					85	
	gct	gga	aat	agc	gca	tat	ttc	ttt	cat	cct	gac	aat	cag	gaa	gat	405
	Ala	Gly	Asn	Ser	Ala	Tyr	Phe	Phe	His	Pro	Asp	Asn	Gln	Glu	Asp	
					90					95					100	
25	gca	gaa	gca	atc	act	cat	ctt	ttc	act	gat	gtt	caa	aat	cga	tat	450
	Ala	Glu	Ala	Ile	Thr	His	Leu	Phe	Thr	Asp	Val	Gln	Asn	Arg	Tyr	
					105					110					115	
	aca	ttc	gcc	ttt	gga	ggt	aat	tat	gat	aga	ctt	gaa	caa	ctt	gct	495
	Thr	Phe	Ala	Phe	Gly	Gly	Asn	Tyr	Asp	Arg	Leu	Glu	Gln	Leu	Ala	
30					120					125					130	
	ggt	aat	ctg	aga	gaa	aat	atc	gag	ttg	gga	aat	ggt	cca	cta	gag	540
	Gly	Asn	Leu	Arg	Glu	Asn	Ile	Glu	Leu	Gly	Asn	Gly	Pro	Leu	Glu	
					135					140					145	
35	gag	gct	atc	tca	gcg	ctt	tat	tat	tac	agt	act	ggt	ggc	act	cag	585
	Glu	Ala	Ile	Ser	Ala	Leu	Tyr	Tyr	Tyr	Ser	Thr	Gly	Gly	Thr	Gln	
					150					155					160	

	ctt cca act ctg gct cgt tcc ttt ata att tgc atc caa atg att	630
	Leu Pro Thr Leu Ala Arg Ser Phe Ile Ile Cys Ile Gln Met Ile	
		165 170 175
5	tca gaa gca gca aga ttc caa tat att gag gga gaa atg cgc acg	675
	Ser Glu Ala Ala Arg Phe Gln Tyr Ile Glu Gly Glu Met Arg Thr	
		180 185 190
	aga att agg tac aac cgg aga tct gca cca gat cct agc gta att	720
	Arg Ile Arg Tyr Asn Arg Arg Ser Ala Pro Asp Pro Ser Val Ile	
		195 200 205
10	aca ctt gag aat agt tgg ggg aga ctt tcc act gca att caa gag	765
	Thr Leu Glu Asn Ser Trp Gly Arg Leu Ser Thr Ala Ile Gln Glu	
		210 215 220
	tct aac caa gga gcc ttt gct agt cca att caa ctg caa aga cgt	810
	Ser Asn Gln Gly Ala Phe Ala Ser Pro Ile Gln Leu Gln Arg Arg	
15		225 230 235
	aat ggt tcc aaa ttc agt gtg tac gat gtg agt ata tta atc cct	855
	Asn Gly Ser Lys Phe Ser Val Tyr Asp Val Ser Ile Leu Ile Pro	
		240 245 250
	atc ata gct ctc atg gtg tat aga tgc gca cct cca cca tcg tca	900
20	Ile Ile Ala Leu Met Val Tyr Arg Cys Ala Pro Pro Pro Ser Ser	
		255 260 265
	cag ttt tct ttg ctt ata agg cca gtg gta cca aat ttt aat gct	945
	Gln Phe Ser Leu Leu Ile Arg Pro Val Val Pro Asn Phe Asn Ala	
		270 275 280
25	gat gtt tgt atg gat cct gag ccc ata gtg cgt atc gta ggt cga	990
	Asp Val Cys Met Asp Pro Glu Pro Ile Val Arg Ile Val Gly Arg	
		285 290 295
	aat ggt cta tgt gtt gat gtt agg gat gga aga ttc cac aac gga	1035
30	Asn Gly Leu Cys Val Asp Val Arg Asp Gly Arg Phe His Asn Gly	
		300 305 310
	aac gca ata cag ttg tgg cca tgc aag tct aat aca gat gca aat	1080
	Asn Ala Ile Gln Leu Trp Pro Cys Lys Ser Asn Thr Asp Ala Asn	
		315 320 325
35	cag ctc tgg act ttg aaa aga gac aat act att cga tct aat gga	1125
	Gln Leu Trp Thr Leu Lys Arg Asp Asn Thr Ile Arg Ser Asn Gly	
		330 335 340

	aag tgt tta act act tac ggg tac agt ccg gga gtc tat gtg atg	1170
	Lys Cys Leu Thr Thr Tyr Gly Tyr Ser Pro Gly Val Tyr Val Met	355
		345 350
5	atc tat gat tgc aat act gct gca act gat gcc acc cgc tgg caa	1215
	Ile Tyr Asp Cys Asn Thr Ala Ala Thr Asp Ala Thr Arg Trp Gln	370
		360 365
	ata tgg gat aat gga acc atc ata aat ccc aga tct agt cta gtt	1260
	Ile Trp Asp Asn Gly Thr Ile Ile Asn Pro Arg Ser Ser Leu Val	385
		375 380
10	tta gca gcg aca tca ggg aac agt ggt acc aca ctt aca gtg caa	1305
	Leu Ala Ala Thr Ser Gly Asn Ser Gly Thr Thr Leu Thr Val Gln	400
		390 395
	acc aac att tat gcc gtt agt caa ggt tgg ctt cct act aat aat	1350
	Thr Asn Ile Tyr Ala Val Ser Gln Gly Trp Leu Pro Thr Asn Asn	415
15		405 410
	aca caa cct ttt gtg aca acc att gtt ggg cta tat ggt ctg tgc	1395
	Thr Gln Pro Phe Val Thr Thr Ile Val Gly Leu Tyr Gly Leu Cys	430
		420 425
	ttg caa gca aat agt gga caa gta tgg ata gag gac tgt agc agt	1440
20	Leu Gln Ala Asn Ser Gly Gln Val Trp Ile Glu Asp Cys Ser Ser	445
		435 440
	gaa aag gct gaa caa cag tgg gct ctt tat gca gat ggt tca ata	1485
	Glu Lys Ala Glu Gln Gln Trp Ala Leu Tyr Ala Asp Gly Ser Ile	460
		450 455
25	cgt cct cag caa aac cga gat aat tgc ctt aca agt gat tct aat	1530
	Arg Pro Gln Gln Asn Arg Asp Asn Cys Leu Thr Ser Asp Ser Asn	475
		465 470
	ata cgg gaa aca gtt gtc aag atc ctc tct tgt ggc cct gca tcc	1575
30	Ile Arg Glu Thr Val Val Lys Ile Leu Ser Cys Gly Pro Ala Ser	490
		480 485
	tct ggc caa cga tgg atg ttc aag aat gat gga acc att tta aat	1620
	Ser Gly Gln Arg Trp Met Phe Lys Asn Asp Gly Thr Ile Leu Asn	505
		495 500
35	ttg tat agt ggg ttg gtg tta gat gtg agg gca tcg gat ccg agc	1665
	Leu Tyr Ser Gly Leu Val Leu Asp Val Arg Ala Ser Asp Pro Ser	520
		510 515

ctt aaa caa atc att ctt tac cct ctc cat ggt gac cca aac caa 1710
Leu Lys Gln Ile Ile Leu Tyr Pro Leu His Gly Asp Pro Asn Gln
525 530 535

5 ata tgg tta cca tta ttt tga 1731
Ile Trp Leu Pro Leu Phe
540

<210> 3

<211> 1731

<212> DNA

10 <213> Ricinus communis

<308> Genbank X03179

<400> 3

atg aaa ccg gga gga aat act att gta ata tgg atg tat gca gtg 45
Met Lys Pro Gly Gly Asn Thr Ile Val Ile Trp Met Tyr Ala Val
-35 -30 -25

gca aca tgg ctt tgt ttt gga tcc acc tca ggg tgg tct ttc aca 90
Ala Thr Trp Leu Cys Phe Gly Ser Thr Ser Gly Trp Ser Phe Thr
-20 -15 -10

tta gag gat aac aac ata ttc ccc aaa caa tac cca att ata aac 135
20 Leu Glu Asp Asn Asn Ile Phe Pro Lys Gln Tyr Pro Ile Ile Asn
-5 -1 1 5 10

ttt	acc	aca	gcg	ggt	gcc	act	gtg	caa	agc	tac	aca	aac	ttt	atc	180
Phe	Thr	Thr	Ala	Gly	Ala	Thr	Val	Gln	Ser	Tyr	Thr	Asn	Phe	Ile	
				15					20					25	

25 aga gct gtt cgc ggt cgt tta aca act gga gct gat gtg aga cat 225
Arg Ala Val Arg Gly Arg Leu Thr Thr Gly Ala Asp Val Arg His

30 35 40

gaa ata cca gtg ttg cca aac aga gtt ggt ttg cct ata aac caa 270
Glu Ile Pro Val Leu Pro Asn Arg Val Gly Leu Pro Ile Asn Gln
30 45 50 55

cgg ttt att tta gtt gaa ctc tca aat cat gca gag ctt tct gtt 315
 Arg Phe Ile Leu Val Glu Leu Ser Asn His Ala Glu Leu Ser Val
 60 65 70

	aca tta gcg ctg gat gtc acc aat gca tat gtg gtc ggc tac cgt	360
	Thr Leu Ala Leu Asp Val Thr Asn Ala Tyr Val Val Gly Tyr Arg	
	75 80 85	
5	gct gga aat agc gca tat ttc ttt cat cct gac aat cag gaa gat	405
	Ala Gly Asn Ser Ala Tyr Phe Phe His Pro Asp Asn Gln Glu Asp	
	90 95 100	
	gca gaa gca atc act cat ctt ttc act gat gtt caa aat cga tat	450
	Ala Glu Ala Ile Thr His Leu Phe Thr Asp Val Gln Asn Arg Tyr	
	105 110 115	
10	aca ttc gcc ttt ggt ggt aat tat gat aga ctt gaa caa ctt gct	495
	Thr Phe Ala Phe Gly Gly Asn Tyr Asp Arg Leu Glu Gln Leu Ala	
	120 125 130	
15	ggt aat ctg aga gaa aat atc gag ttg gga aat ggt cca cta gag	540
	Gly Asn Leu Arg Glu Asn Ile Glu Leu Gly Asn Gly Pro Leu Glu	
	135 140 145	
	gag gct atc tca gcg ctt tat tat tac agt act ggt ggc act cag	585
	Glu Ala Ile Ser Ala Leu Tyr Tyr Tyr Ser Thr Gly Gly Thr Gln	
	150 155 160	
20	ctt cca act ctg gct cgt tcc ttt ata att tgc atc caa atg att	630
	Leu Pro Thr Leu Ala Arg Ser Phe Ile Ile Cys Ile Gln Met Ile	
	165 170 175	
	tca gaa gca gca aga ttc caa tat att gag gga gaa atg cgc acg	675
	Ser Glu Ala Ala Arg Phe Gln Tyr Ile Glu Gly Glu Met Arg Thr	
	180 185 190	
25	aga att agg tac aac cgg aga tct gca cca gat cct agc gta att	720
	Arg Ile Arg Tyr Asn Arg Arg Ser Ala Pro Asp Pro Ser Val Ile	
	195 200 205	
30	aca ctt gag aat agt tgg ggg aga ctt tca act gca att caa gag	765
	Thr Leu Glu Asn Ser Trp Gly Arg Leu Ser Thr Ala Ile Gln Glu	
	210 215 220	
	tct aac caa gga gcc ttt gct agt cca att caa ctg caa aga cgt	810
	Ser Asn Gln Gly Ala Phe Ala Ser Pro Ile Gln Leu Gln Arg Arg	
	225 230 235	
35	aat ggt tcc aaa ttc agt gtg tac gat gtg agt ata tta atc cct	855
	Asn Gly Ser Lys Phe Ser Val Tyr Asp Val Ser Ile Leu Ile Pro	
	240 245 250	

	atc	ata	gct	ctc	atg	gtg	tat	aga	tgc	gca	cct	cca	cca	tcg	tca	900
	Ile	Ile	Ala	Leu	Met	Val	Tyr	Arg	Cys	Ala	Pro	Pro	Pro	Ser	Ser	
					255					260					265	
5	cag	ttt	tct	ttg	ctt	ata	agg	cca	gtg	gta	cca	aat	ttt	aat	gct	945
	Gln	Phe	Ser	Leu	Leu	Ile	Arg	Pro	Val	Val	Pro	Asn	Phe	Asn	Ala	
					270					275					280	
	gat	gtt	tgt	atg	gat	cct	gag	ccc	ata	gtg	cgt	atc	gta	ggg	cga	990
	Asp	Val	Cys	Met	Asp	Pro	Glu	Pro	Ile	Val	Arg	Ile	Val	Gly	Arg	
					285					290					295	
10	aat	ggg	cta	tgt	gtt	gat	gtt	agg	gat	gga	aga	ttc	cac	aac	gga	1035
	Asn	Gly	Leu	Cys	Val	Asp	Val	Arg	Asp	Gly	Arg	Phe	His	Asn	Gly	
					300					305					310	
15	aac	gca	ata	cag	ttg	tgg	cca	tgc	aag	tct	aat	aca	gat	gca	aat	1080
	Asn	Ala	Ile	Gln	Leu	Trp	Pro	Cys	Lys	Ser	Asn	Thr	Asp	Ala	Asn	
					315					320					325	
	cag	ctc	tgg	act	ttg	aaa	aga	gac	aat	act	att	cga	tct	aat	gga	1125
	Gln	Leu	Trp	Thr	Leu	Lys	Arg	Asp	Asn	Thr	Ile	Arg	Ser	Asn	Gly	
					330					335					340	
20	aag	tgt	tta	act	act	tac	ggg	tac	agt	ccg	gga	gtc	tat	gtg	atg	1170
	Lys	Cys	Leu	Thr	Thr	Tyr	Gly	Tyr	Ser	Pro	Gly	Val	Tyr	Val	Met	
					345					350					355	
	atc	tat	gat	tgc	aat	act	gct	gca	act	gat	gcc	acc	cgc	tgg	caa	1215
	Ile	Tyr	Asp	Cys	Asn	Thr	Ala	Ala	Thr	Asp	Ala	Thr	Arg	Trp	Gln	
					360					365					370	
25	ata	tgg	gat	aat	gga	acc	atc	ata	aat	ccc	aga	tct	agt	cta	gtt	1260
	Ile	Trp	Asp	Asn	Gly	Thr	Ile	Ile	Asn	Pro	Arg	Ser	Ser	Leu	Val	
					375					380					385	
30	tta	gca	gcg	aca	tca	ggg	aac	agt	ggg	acc	aca	ctt	aca	gtg	caa	1305
	Leu	Ala	Ala	Thr	Ser	Gly	Asn	Ser	Gly	Thr	Thr	Leu	Thr	Val	Gln	
					390					395					400	
	acc	aac	att	tat	gcc	gtt	agt	caa	ggg	tgg	ctt	cct	act	aat	aat	1350
	Thr	Asn	Ile	Tyr	Ala	Val	Ser	Gln	Gly	Trp	Leu	Pro	Thr	Asn	Asn	
					405					410					415	
35	aca	caa	cct	ttt	gtg	aca	acc	att	gtt	ggg	cta	tat	ggg	ctg	tgc	1395
	Thr	Gln	Pro	Phe	Val	Thr	Thr	Ile	Val	Gly	Leu	Tyr	Gly	Leu	Cys	
					420					425					430	

	ttg caa gca aat agt gga caa gta tgg ata gag gac tgt agc agt	1440
	Leu Gln Ala Asn Ser Gly Gln Val Trp Ile Glu Asp Cys Ser Ser	
	435 440 445	
5	gaa aag gct gaa caa cag tgg gct ctt tat gca gat ggt tca ata	1485
	Glu Lys Ala Glu Gln Gln Trp Ala Leu Tyr Ala Asp Gly Ser Ile	
	450 455 460	
	cgt cct cag caa aac cga gat aat tgc ctt aca agt gat tct aat	1530
	Arg Pro Gln Gln Asn Arg Asp Asn Cys Leu Thr Ser Asp Ser Asn	
	465 470 475	
10	ata cgg gaa aca gtt gtc aag atc ctc tct tgt ggc cct gca tcc	1575
	Ile Arg Glu Thr Val Val Lys Ile Leu Ser Cys Gly Pro Ala Ser	
	480 485 490	
15	tct ggc caa cga tgg atg ttc aag aat gat gga acc att tta aat	1620
	Ser Gly Gln Arg Trp Met Phe Lys Asn Asp Gly Thr Ile Leu Asn	
	495 500 505	
	ttg tat agt ggg ttg gtg tta gat gtg agg gca tcg gat ccg agc	1665
	Leu Tyr Ser Gly Leu Val Leu Asp Val Arg Ala Ser Asp Pro Ser	
	510 515 520	
20	ctt aaa caa atc att ctt tac cct ctc cat ggt gac cca aac caa	1710
	Leu Lys Gln Ile Ile Leu Tyr Pro Leu His Gly Asp Pro Asn Gln	
	525 530 535	
	ata tgg tta cca tta ttt tga	1731
	Ile Trp Leu Pro Leu Phe	
	540	
25	<210>	4
	<211>	10
	<212>	PRT
	<213>	Human immunodeficiency virus
	<400>	4
30	Val Ser Gln Asn Tyr Pro Ile Val Gln Asn	
	1 5 10	
	<210>	5

<211> 30
 <212> DNA
 <213> Artificial Sequence
 <220>
 5 <223> Encodes the modified proricin linker sequence of SEQ ID NO:4.
 <400> 5
 gtt tct caa aac tac cca att gtt caa aat 30
 Val Ser Gln Asn Tyr Pro Ile Val Gln Asn
 10 1 5 10
 <210> 6
 <211> 29
 <212> DNA
 <213> Artificial Sequence
 15 <220>
 <223> Primer for amplifying the 5' portion of the preproricin gene and incorporating a SacI recognition site.
 <400> 6
 ctcgagctct gaaaccggga ggaaataact 29
 20 <210> 7
 <211> 50
 <212> DNA
 <213> Artificial Sequence
 <220>
 25 <223> Primer for amplifying the 5' portion of the preproricin gene, mutating the linker sequence, and incorporating a MfeI recognition site.

<400> 7

ttgaacaatt gggtagtttt gagaaacaaa ctgtgacgat ggtggaggtg 50

<210> 8

<211> 51

5 <212> DNA

<213> Artificial Sequence

<220>

<223> Primer for amplifying the 3' portion of the preproricin
gene, mutating the linker sequence, and incorporating a
MfeI recognition site.

10 <400> 8

ctaccaatt gttcaaaatt ttaatgctga tgtttgatg g 51

<210> 9

<211> 29

15 <212> DNA

<213> Artificial Sequence

<220>

<223> Primer for amplifying the 3' portion of the preproricin
gene and incorporating an XhoI recognition site.

20 <400> 9

ctcctcgagt ttaagccatc tattttcat 29

<210> 10

<211> 1805

<212> DNA

25 <213> Ricinus communis

<400> 10

ctcgagctct gaaaccggga ggaaatacta ttgtaatatg g atg tat 47
Met Tyr

5	gca	gtg	gca	aca	tgg	ctt	tgt	ttt	gga	tcc	acc	tca	ggg	tgg	tct	92
	Ala	Val	Ala	Thr	Trp	Leu	Cys	Phe	Gly	Ser	Thr	Ser	Gly	Trp	Ser	
			-20					-15					-10			
	ttc	aca	tta	gag	gat	aac	aac	ata	ttc	ccc	aaa	caa	tac	cca	att	137
	Phe	Thr	Leu	Glu	Asp	Asn	Asn	Ile	Phe	Pro	Lys	Gln	Tyr	Pro	Ile	
			-5					1				5				
10	ata	aac	ttt	acc	aca	gcg	ggg	gcc	act	gtg	caa	agc	tac	aca	aac	182
	Ile	Asn	Phe	Thr	Thr	Ala	Gly	Ala	Thr	Val	Gln	Ser	Tyr	Thr	Asn	
		10					15					20				
	ttt	atc	aga	gct	gtt	cgc	ggg	cgt	tta	aca	act	gga	gct	gat	gtg	227
	Phe	Ile	Arg	Ala	Val	Arg	Gly	Arg	Leu	Thr	Thr	Gly	Ala	Asp	Val	
15		25					30					35				
	aga	cat	gaa	ata	cca	gtg	ttg	cca	aac	aga	gtt	ggg	ttg	cct	ata	272
	Arg	His	Glu	Ile	Pro	Val	Leu	Pro	Asn	Arg	Val	Gly	Leu	Pro	Ile	
		40					45					50				
	aac	caa	cgg	ttt	att	tta	gtt	gaa	ctc	tca	aat	cat	gca	gag	ctt	317
20	Asn	Gln	Arg	Phe	Ile	Leu	Val	Glu	Leu	Ser	Asn	His	Ala	Glu	Leu	
		55					60					65				
	tct	gtt	aca	tta	gcg	ctg	gat	gtc	acc	aat	gca	tat	gtg	gtc	ggc	362
	Ser	Val	Thr	Leu	Ala	Leu	Asp	Val	Thr	Asn	Ala	Tyr	Val	Val	Gly	
		70					75					80				
25	tac	cgt	gct	gga	aat	agc	gca	tat	ttc	ttt	cat	cct	gac	aat	cag	407
	Tyr	Arg	Ala	Gly	Asn	Ser	Ala	Tyr	Phe	Phe	His	Pro	Asp	Asn	Gln	
		85					90					95				
	gaa	gat	gca	gaa	gca	atc	act	cat	ctt	ttc	act	gat	gtt	caa	aat	452
	Glu	Asp	Ala	Glu	Ala	Ile	Thr	His	Leu	Phe	Thr	Asp	Val	Gln	Asn	
30		100					105					110				
	cga	tat	aca	ttc	gcc	ttt	ggg	ggg	aat	tat	gat	aga	ctt	gaa	caa	497
	Arg	Tyr	Thr	Phe	Ala	Phe	Gly	Gly	Asn	Tyr	Asp	Arg	Leu	Glu	Gln	
		115					120					125				
35	ctt	gct	ggg	aat	ctg	aga	gaa	aat	atc	gag	ttg	gga	aat	ggg	cca	542
	Leu	Ala	Gly	Asn	Leu	Arg	Glu	Asn	Ile	Glu	Leu	Gly	Asn	Gly	Pro	

	130	135	140	
	cta gag gag gct atc tca gcg ctt tat tat tac agt act ggt ggc 587 Leu Glu Glu Ala Ile Ser Ala Leu Tyr Tyr Tyr Ser Thr Gly Gly	145	150	155
5	act cag ctt cca act ctg gct cgt tcc ttt ata att tgc atc caa 632 Thr Gln Leu Pro Thr, Leu Ala Arg Ser Phe Ile Ile Cys Ile Gln	160	165	170
10	atg att tca gaa gca gca aga ttc caa tat att gag gga gaa atg 677 Met Ile Ser Glu Ala Ala Arg Phe Gln Tyr Ile Glu Gly Glu Met	175	180	185
	cgc acg aga att agg tac aac cgg aga tct gca cca gat cct agc 722 Arg Thr Arg Ile Arg Tyr Asn Arg Arg Ser Ala Pro Asp Pro Ser	190	195	200
15	gta att aca ctt gag aat agt tgg ggg aga ctt tca act gca att 767 Val Ile Thr Leu Glu Asn Ser Trp Gly Arg Leu Ser Thr Ala Ile	205	210	215
	caa gag tct aac caa gga gcc ttt gct agt cca att caa ctg caa 812 Gln Glu Ser Asn Gln Gly Ala Phe Ala Ser Pro Ile Gln Leu Gln	220	225	230
20	aga cgt aat ggt tcc aaa ttc agt gtg tac gat gtg agt ata tta 857 Arg Arg Asn Gly Ser Lys Phe Ser Val Tyr Asp Val Ser Ile Leu	235	240	245
25	atc cct atc ata gct ctc atg gtg tat aga tgc gca cct cca cca 902 Ile Pro Ile Ile Ala Leu Met Val Tyr Arg Cys Ala Pro Pro Pro	250	255	260
	tcg tca cag ttt gtt tct caa aac tac cca att gtt caa aat ttt 947 Ser Ser Gln Phe Val Ser Gln Asn Tyr Pro Ile Val Gln Asn Phe	265	270	275
30	aat gct gat gtt tgt atg gat cct gag ccc ata gtg cgt atc gta 992 Asn Ala Asp Val Cys Met Asp Pro Glu Pro Ile Val Arg Ile Val	280	285	290
	ggt cga aat ggt cta tgt gtt gat gtt agg gat gga aga ttc cac 1037 Gly Arg Asn Gly Leu Cys Val Asp Val Arg Asp Gly Arg Phe His	295	300	305
35	aac gga aac gca ata cag ttg tgg cca tgc aag tct aat aca gat 1082 Asn Gly Asn Ala Ile Gln Leu Trp Pro Cys Lys Ser Asn Thr Asp			

	310	315	320	
	gca aat cag ctc tgg act	ttg aaa aga gac aat	act att cga tct	1127
	Ala Asn Gln Leu Trp Thr	Leu Lys Arg Asp Asn	Thr Ile Arg Ser	
	325	330	335	
5	aat gga aag tgt tta act	act tac ggg tac agt	ccg gga gtc tat	1172
	Asn Gly Lys Cys Leu Thr	Thr Tyr Gly Tyr Ser	Pro Gly Val Tyr	
	340	345	350	
10	gtg atg atc tat gat tgc	aat act gct gca act	gat gcc acc cgc	1217
	Val Met Ile Tyr Asp Cys	Asn Thr Ala Ala Thr	Asp Ala Thr Arg	
	355	360	365	
	tgg caa ata tgg gat aat	gga acc atc ata aat	ccc aga tct agt	1262
	Trp Gln Ile Trp Asp Asn	Gly Thr Ile Ile Asn	Pro Arg Ser Ser	
	370	375	380	
15	cta gtt tta gca gcg aca	tca ggg aac agt ggt	acc aca ctt aca	1307
	Leu Val Leu Ala Ala Thr	Ser Gly Asn Ser Gly	Thr Thr Leu Thr	
	385	390	395	
	gtg caa acc aac att tat	gcc gtt agt caa ggt	tgg ctt cct act	1352
	Val Gln Thr Asn Ile Tyr	Ala Val Ser Gln Gly	Trp Leu Pro Thr	
	400	405	410	
20	aat aat aca caa cct ttt	gtg aca acc att gtt	ggg cta tat ggt	1397
	Asn Asn Thr Gln Pro Phe	Val Thr Thr Ile Val	Gly Leu Tyr Gly	
	415	420	425	
25	ctg tgc ttg caa gca aat	agt gga caa gta tgg	ata gag gac tgt	1442
	Leu Cys Leu Gln Ala Asn	Ser Gly Gln Val Trp	Ile Glu Asp Cys	
	430	435	440	
	agc agt gaa aag gct gaa	caa cag tgg gct ctt	tat gca gat ggt	1487
	Ser Ser Glu Lys Ala Glu	Gln Gln Trp Ala Leu	Tyr Ala Asp Gly	
	445	450	455	
30	tca ata cgt cct cag caa	aac cga gat aat tgc	ctt aca agt gat	1532
	Ser Ile Arg Pro Gln Gln	Asn Arg Asp Asn Cys	Leu Thr Ser Asp	
	460	465	470	
	tct aat ata cgg gaa aca	gtt gtc aag atc ctc	tct tgt ggc cct	1577
	Ser Asn Ile Arg Glu Thr	Val Val Lys Ile Leu	Ser Cys Gly Pro	
	475	480	485	
35	gca tcc tct ggc caa cga	tgg atg ttc aag aat	gat gga acc att	1622
	Ala Ser Ser Gly Gln Arg	Trp Met Phe Lys Asn	Asp Gly Thr Ile	

	490	495	500	
	tta aat ttg tat agt ggg ttg gtg tta gat gtg agg gca tcg gat			1667
	Leu Asn Leu Tyr Ser Gly Leu Val Leu Asp Val Arg Ala Ser Asp			
	505	510	515	
5	ccg agc ctt aaa caa atc att ctt tac cct ctc cat ggt gac cca			1712
	Pro Ser Leu Lys Gln Ile Ile Leu Tyr Pro Leu His Gly Asp Pro			
	520	525	530	
	aac caa ata tgg tta cca tta ttt tgatagacag attactctct			1756
	Asn Gln Ile Trp Leu Pro Leu Phe			
10	535	540		
	tgacagtgtgt atgtcctgcc atgaaaatag atggcttaaa ctcgaggag			1805
	<210>	11		
	<211>	10		
	<212>	PRT		
15	<213>	Human immunodeficiency virus		
	<400>	11		
	Ser Ala Thr Ile Met Met Gln Arg Gly Asn			
	1	5	10	
	<210>	12		
20	<211>	12		
	<212>	PRT		
	<213>	Human immunodeficiency virus		
	<400>	12		
	Val Ser Gln Asn Tyr Pro Ile Val Gln Asn Phe Asn			
25	1	5	10	
	<210>	13		
	<211>	12		

<212> PRT
 <213> Human immunodeficiency virus
 <400> 13
 5 Ser Ala Thr Ile Met Met Gln Arg Gly Asn Phe Asn
 1 5 10

 <210> 14
 <211> 12
 <212> PRT
 <213> Ricinus communis
 10 <400> 14
 Val Ser Ile Leu Ile Pro Ile Ile Ala Leu Met Val
 1 5 10

 <210> 15
 <211> 5
 15 <212> PRT
 <213> Rous sarcoma virus
 <400> 15
 Pro Pro Pro Pro Thr
 1 5
 20 <210> 16
 <211> 4
 <212> PRT
 <213> Homo sapiens
 <400> 16
 25 Lys Asp Glu Leu
 1

<210> 17
<211> 5
<212> PRT
<213> Human immunodeficiency virus
5 <400> 17
Gly Ala Arg Ala Ser
1 5

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/05282

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 38/00, 39/40

US CL : 514/21; 424/183.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/21; 424/183.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DIALOG, BIOSIS, EMBASE, MEDLINE, CASEARCH, toxins, ricin, rips, hiv, antiviral, activated, protease, protein synthesis
inactivating toxin

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,981,493 A (LAGRONE) 09 November 1999, entire document.	1-45

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* Later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A document defining the general state of the art which is not considered to be of particular relevance	* X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* B earlier document published on or after the international filing date	* Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* A document member of the same patent family
* O document referring to an oral disclosure, use, exhibition or other means	
* P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

18 JULY 2001

Date of mailing of the international search report

26 JUL 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-5930

Authorized officer

HANKYEL T. PARK, PH.D.

Telephone No. (703) 308-0196